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INTRODUCTION 
   “lXh<hK!dmz<Ofib<!lVf<oke!ziGl<!
! ! ! !lXh<hK!dtOfib<!lVf<okes<!siZl<!
! ! ! !lXh<hK!-eqOfib<!uivi!kqVg<g!
! ! ! !lXh<hK!siOu!lVf<keziOl”!
- kqVlf<kqvl<< << << <!
 Siddha system of Medicine is one among the fascinating branches of 
indigenous medicine which made its origin in the soul of Tamil Nadu. 
 Siddha system isa  unique system of medicine for maintaining health or 
treatment for disease. 
 Siddha system of medicine is not a discovery but a gradual evolution 
during successive periods of history.  It owes its progress to great men.  Who 
have not only enriched the Science, but also society and civilization as a 
whole. 
 Generally, original of this system is associated with Siddhars, (mean 
super natural powers - THIRUMANDIRAM) who aimed for ageless body to 
achieve their highest spiritual goal. 
 Siddhars the founders of Siddha Medicine had perceived and announced 
the use for herbs, minerals, motals and non-metals as a remedy for variable 
incurable aliments 
 Siddhar system of Medicine consist of the three dhosas namely, 
 Vali  Air + Aagayam 
 Azhal  Fire 
 Iyam  water+Earth 
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 Three dhosas are the essential constituents of the living body which are 
responsible for regulating all the body functions. 
 Siddha System of Medicine lays great emphasis on early changes caused 
by disturbances of dhosas in the whole body as a result of excessive turnover 
the development of disease in a fullfledged manner. 
 This concept of Thirumoolar is much the same with our WHO’s 
declaration that “ Health is a state of complete physical, mental, social well 
being and not merely an absence of disease”. 
 It is evident that infectious disease kill over 17 Million people a year and 
WHO warns of this global crisis, The struggle to control infectious disease has 
reached  critical stage”. 
 Kuzhandhai Marauthuvam constitutes the study of the child from 
conception and the development of the fetus upto childhood illness. 
 Of the Paediatric infectious diseases, Manjal Kamalai is one among them 
which must be promptly treated and  recurrences prevented.  So my dissertation 
drug “KARISALANKANNI CHURNAM”, is expected not only to reduce 
signs, symptoms and recurrence of Manjal Kamalai but also acts as an 
hepatoprotective. 
 The great Principles of Siddha have to explained in forms of modern 
science in order, to give the recognition and also to rediscover the truths.  So in 
the present dissertation, an integrated attempt is made by considering both 
Siddha aspects and corresponding Modern Medical aspects. 
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AIM & OBJECTIVES 
AIM: 
 To evaluate the efficacy of the trial drug.“KARISALANKANNI 
CHURNAM” in the treatment of “MANJAL KAMALAI” without any side 
effects. 
 Truth among the people that this disease is mostly curable in our 
traditional Medicine of Siddha system. 
 If proper attention has not been given, it may even be to fatal .So proper 
treatment and care is to be taken at the earliest. 
OBJECTIVES: 
 To create awareness among the patients and their parents about the 
disease and its complications and educate them to improve their poor 
environmental and personal hygiene, poor sanitary and dietary habits. 
 To know the extent of correlation of Etiopathogenesis, signs and 
symptoms of MANJAL KAMALAI with JAUNDICE. 
 To study the relationship of age, sex, race, environment, Socio-
economic status in the incidence of the disease 
 
 To  study the Biochemical and Pharmacological actions of the trial 
drug along with analysis of Siddha investigation techniques.  Such 
as Envagai thervu, Neerkuri, Neikuri towards the efficacy of the 
medicine. 
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REVIEW OF LITERATURE 
SIDDHA ASPECT: 
   lR<st<!Ofib<< < << < << < <!
OuX!ohbIgt<;<<< !
 kQ;rs; fhkhiy 
 fhkhiy 
 gpj;J Neha; 
 fhkyh 
 fhkpyh 
 gpj;j fhkhiy 
       -A+fp itj;jpa rpe;jhkzp ; ;; ;; ;  
-bz<H;<<< !
dml<hqe<!Okiz<?!su<U?!fQI!Lkzqbjugt<!hqk<kfqxl<!Ohiz<!nkiuK!
lR<stig!gi{h<hMl</!!-u<uqbikq!Lg<gqblib<!Gpf<jkgTg<Gg<!gi[l</!
- sil<hsqul<!hqt<jt!ngvikq< < << < << < < !
! dmzqz<! -vk<kl<! ux<xq! hqk<kfQI! nkqgiqk<K! Lgl<?! giz<! uQr<Gl</!!
lR<st<! Ohiz<! fQiqxr<Gl<?! g{<! ouTk<kqVg<Gl<?! lzl<! sqg<Gl<?! ! gjth<H?!
nskq!gi[l</!
- dbqIgig<Gl<!sqk<k!lVk<Kul<;!< < < < << < < < << < < < < !
- Gpf<jkg<G!uVl<!gilijz!hg<gl<;253< < < < << < < < << < < < < !
Okgk<kqz<! -vk<kl<! ogm<M! kjs! ouTk<K! =vz<! ogm<M! hzuixie!
Ovigr<gjt!uqjtuqg<Gl</!
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- Nk<l!vg<< << << <]ilqIk!juk<kqb!siv!sr<gqvigl< << << < << <<!
! fvl<Hgjt! nEsiqk<K! hqk<k! vk<k! lilqsk<jk! kgqg<g! d{<miuK!
hi{<M!Ovig!LkqIs<sqbqz<!hqk<k!u <^Kg<gjt!Hsqh<hkiZl<!d{<miuK/!
.nhqkie!sqf<kil{q<<< !
!!!!!!!sqXfQI?! g{<?! fi?! dmz<! biUl<! lR<st<! fqxlig! -Vk<kz<!
we<hkie! Ofibil<! “gilijz”! we<El<! hkl<! “gill<! nz<jz”! weh<!
ohiVt<hML</! ! nkiuK! “wkqZl<! -s<jsbqz<zijl”jbg<! Gxqg<Gl<!
we<hkil</!
! hqk<Kju! -bx<jgg<G! lixig! outqk<Okix<xlib<g<! GVkqBme<!
gzf<kqVg<Gl<!Ofibikziz<!“hqk<KOfib<”!weh<!ohbvibqx<X!wezil</!
! dmz<!Nkqbf<kLl<!lR<st<!fqxligk<!Okie<Xukiz<!“lR<st<!Ofib<”!
weh<!ohbvibqx<X!wezil</!
!!!!!!!!!!!!.!!!!b,gqLeq!
Ofib<!uVl<!upq;< << << < !
! kibqe<! gIh<h! gizk<kqz<! sil<hz<?! l{<! Lkzqbux<jxs<! sih<hqMr<!
ogm<m!hpg<gr<gtqeiz<!Gpf<jkbqe<!dml<hqz<!-vk<kl<!ogm<M?!sQv{!sg<kq!
Gjxf<K?!hqk<kl<!nkqgiqk<K/!nkeiz<!dml<H!LPuKl<!lR<st<!fqxligg<!
gi[l<!/!
- sil<hsqul<!hqt<jt< < << < << < < !ngvikq;!
! kibqml<! hiz<! nVf<Kl<! 2! Lkz<! 4! ubKg<Gt<! -Vg<Gl<!
Gpf<jkgTg<G! lR<st<! Ofib<! uVukx<gie! giv{l<! we<eoue<xiz<?!
kibieut<! npz<! Gx<xk<jk! nkqgh<hMk<Kl<! d{U! lx<Xl<! osbz<!
Oux<Xjlbiz<!kibqmlqVf<K!Gpf<jkg<G!osz<Zl<!kib<h<hiz<!Gx<xljmf<K!
Gpf<jkg<G!Ofijbk<!kVuqg<gqe<xe/!!!
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.squki[h<hqt<jtbqe<!< < << < << < <
Gpf<jk!Vk<Kul<< < << < << < <!
!!!!!4!Lkz<! 23!ubKg<Gt<!-Vg<Gl<!Gpf<jkgTg<G!Sgikivlx<x! fQI!
lx<Xl<! d{uiZl<?! w{<o{b<?! ofb<?! ogiPh<H! Ohie<x! d{Uh<!
ohiVm<gjt! lqGf<ktU! d{<hkiZl<?! hqk<kh<! jhbqz<! gz<?! gm<cgt<!
dVuiukiZl<?! GVkqjbg<! Ogm<mjmbs<! osb<Bl<! lVf<K! ujggtiZl<!
GVkqbqe<!ue<jl!ogm<M! hqk<kfQI! ke<etuqz<! lqGf<K!GVkqBme<! gzf<K!
lR<st<!Ofibqe<!GxqG{r<gt<!Okie<Xl</!
- squki[h<hqt<jtbqe<!Gpf<jk!lVk<Kul<< < < < < << < < < < << < < < < <!
 kQg<Gx<xk<jkBl<!Jbk<jkBl<!ohVg<gg<%cb!u{uikqs<!osbz<gtiZl<?!
 ntUg<G!lqR<sqb!d{juBl<!dm<ogit<TukiZl<!
 -g<giv{r<gt<!nsQv{L{<mib<?!Ogmjmf<k!kQ!Jbg<!Gx<xr<gtqetuig!
uiBg<gTl<?!GVkqBl<!ogm<M!uzh<him<Czjzk<!kig<gq!kihqkL{<miGl<!
 hqk<K! fQjv! -bx<jg! upqbqz<! osz<zouim<milz<! kMk<K?! GVkqBme<!
gzg<gs<!osb<kz<!!
 dmZXh<Hgtigqb! sjk?! Okiz<?! g{<?! fgg<g{<?! fig<G?! d{<{ig<G!
Lkzqbux<xqz<! GVkqObiM! hqk<KfQI! OsI<fK! kr<Gukiz<! -f<Ofib<!
hqxg<Gl</!
 /g{<lzl<?! giKlzl<?! &g<Glzl<?! -jugTr<! %m! lR<st<!
fqxk<jkbjmBl<?!
 dmz<!Nkqbf<kLl<!lR<st<!fqxk<jk!njmBl<!
 w{<o{b<?!ofb<?!ogiPh<h!-ux<jx!lqGkqbig!d{<[ukiZl<?!
 K~b<jlbx<x!fQjvh<!hVGukiZl<!
 K~b<jlbx<x!d{ju!d{<[ukiZl<!
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 lK! ujggjt! nVf<Kkz<! Ngqb! giv{r<gtiz<! Ofib<gqVlqgt<!
hqk<kh<jhjbk<!kig<gq!kihqkljmb<s!osb<K!uqMl</!
 -bx<jgbqOzOb! Ofib<! wkqIh<Hs<! sg<gq! -e<jl?! -f<Ofijb!
d{<mig<Gl<! gqVlqgt<! Ngqb! giv{k<kiz<! hqk<kh<jhk<!
kihqkljmgqxK/!
 hqk<kh<hjbqz<! gm<c?! gz<! -ux<xqz<! giv{lig! hqk<kfitl<!
njmhMukiZl<?!-f<Ofib<!uVgqxK/!
 GVkqjbg<!Ogmjmbs<!osb<Bl<!lVf<K!ujggtiZl<?!
 hvl<hjvbig!uVl<!-vk<k!Ofib<gtiZl<!!
 GtqI!Svk<kiZl<!
!
!!!!!Olx<%iqb! giv{r<gtiz<! hqk<kfQI! ke<! -bx<jg! upqbqz<!
osz<zilz<! GVkqbqz<! gzf<K! GVkqbqjeg<! Ogmjmbs<! osb<ukiz<!
-f<Ofib<!uVgqxK/!!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!.b,gq!Leq!
Physiological Jaundice;!hqxf<k!Gpf<jk!dmz<!lR<st<!< < < < << < < < << < < < < ogi{<miz<;< << << < !
! hqxg<Gl<!Gpf<jkgtqz<!SliI!&e<xqoziV!higk<kqx<G!hqxf<K!-v{<M!
&e<X!uivk<Kg<Gt<tig!dml<ohz<zil<!lR<st<!h,sqeK!Ohie<x!
fqxL{<miuK{<M?!
! Suis! GjxU?! Sk<k! Ngiblqz<zik! -V{<m! njxgtqzqVh<hK?!
GtqIf<k! gix<XhMuK?! gizg<gqvlk<Kg<G! Lf<kqh<! hqxh<hK! Lkzqb!
giv{r<gtqeiz<! -K! d{<miGl</! ! Neiz<! yV! uivl<! hk<K!
fiTg<Gt<tig! kieib<! lixquqMl</! ! nu<uiX! 21! fim<gTg<G! Olzig!
Gpf<jkbqe<! dmz<! lR<stqk<K! -Vf<kiz<! nK! Ofib<fqjzjbg<! gim<Ml<!
lR<st<!Ofib<!wek<!okiqf<K!ogit<tUl</!
- nMg<gjt!juk<kqb!sqf<kil{q!wEl<< < < << < < << < < <!
!!!!!!!!!!!!!!!!!!!!!!!!!!!nx<H<<< k!sqf<kil{q!hg<gl<!< < << < << < < .4!!
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  Like everything in human body, breast milk can also be 
afflicated by the imbalance of the three constituents of the body, vatha, 
pitha kapha.  This imbalance can affect the quality of mother’s milk and 
bring about problem in infants.                          
-Siddha System of Paediatrics 
 
hizgI! siQvk<kqz<! wPl<! gilijz! OfibieK! Le<o\e<l!
Okisk<kiZl<?! dmzqz<! ogikqk<okPl<! hqk<kk<kqe<! $m<ceiZl<?! kib<!
kf<jkbiqe<!lel<!Ofiu!fmf<kiZl<!dmzqz<!ouh<H!nkqgiqk<K!wPukiZl<!
gilijz!Gpf<jkjb!n[gqxK/!
! ! ! ! ! ! lkjz!Ofib<!okiGkq!hGkq!<<< I!
“lR<st<!Ofib<!fqkiel<;!
nxqbOu!lieqmIg<G!ntuqz<zi!si <^kqvk<jk!!
ofxqBmEjvk<k!F~zib<!fqjzhm!OgiIjubigq!
Okxqb!Ofib<gt<!ogz<zil<!sqgqs<jsjb!osb<b!Ou{<c!
gQXme<!dhOksqk<k!Gpf<jk!Ouz<!LVge<!gih<Oh/! ! !
!
gih<hqe<El<!osiz<Oue<!OgT!gVkqb!lR<st<!Ofibqe<!
OfIh<hqe<El<!liiqobie<Xl<!Ofcb!gilijz!obie<Xl<!
Wx<hqe<El<!lR<st<!we<El<!-h<hc!&e<X!Ovigl<!
OsIh<hqe<El<!sQmVg<gib<!kqV!nVt<!LVge<!gih<Oh/”!! !
Lx<Gxq!G{r<gt<;< < << < << < < !
“!hVgOu!dt<tr<gi!Zt<tr<!jggt<!
! ! ! hgI!Lgr<g{<![ml<Hlqg!ouTh<H!gi[r<!
!!!!!gVgOu!giz<jgg!Otib<s!ziGr<!
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! ! ! gelie!fMg<gqOb!-jth<H{<mig<GR<!
SVgOu!lzf<kiEl<!ux{<M!gm<Mf<!
! ! ! K~bLg!lR<stqm!fqxl!kiGl<!
ouVgOu!uQg<glib<g<!gjth<H{<!miGl<!
! ! ! lqgg<giK!lf<kf<kjz!geh<H{<!miGl<”!
- b,gq!Leq!
 lR<st<!Ofibqz<!dt<tr<giz<?!jg?!Lgl<?!g{<?!dml<H!-jugt<!
ouTk<kz<!
 jggiz<!OsiIujmkz<?!dmz<!TfMg<gz<?!
 wVgm<Mh<hm<M!kQb<f<K!outqbikz<!
Olx<%xqb! GxqG{r<gjtg<! gim<c! dmz<! LPuKl<! lR<st<! fqxk<jk!
njmBl</!
 uQg<gl<?! gjth<H?! giKlf<kl<! LkzqbjugTl<!d{<migg<! %Ml<!
we!b,gqLeq!%XgqxiI/!
lR<sm<!gilijzg<!GxqG{l<;< < < << < < << < < < !
“g{<[me<!sqXfQI!fig<G!
! ! ! g{g<gOu!lR<sm<!Ohizil<!
!w{<{qb!Svr<gt<!uif<kq!
! ! ! obMk<kqM!lbg<g!Lkz<!
!u{<{lib<!&g<gq!eQVl<!
! ! ! uck<kqMl<!ubqx<X!Oeibil<!
!f{<[lR<!sm<gi!lijz!
! ! ! ficb!G{r<gt<!kiOe!
!G{<cbg<!gvlq!Vf<kiz<!
! ! ! GTh<jhbib<!Lgr<giz<!uQr<Gl<!
!uq{<cm!vk<kl<!ux<Xl<!
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! ! ! ouKh<HOlz<!uqziuqz<!Okie<Xl<!
!h{<cbqe<!lzLR<!sqg<gqh<!
! ! ! hSlR<sm<!sqXfQ!viGl</!
!g{<cbib<g<!g{<ou!Tg<G!
! ! ! lR<sm<!lijz!biOl”!
- hizuigml<?!hg<g!w{<!689< < << < << < < !
!
!
ohiVt<;<<< !
 lR<sm<!gilijz!Ofibqz<!g{<?!sqXfQI?!fi!-jugt<!lR<st<!
fqxl<!ohXl</!
 Svl<!giBl<?!uif<kq!gi[l<!
 lbg<gL{<miGl<?!dmz<!DKl<!
 &g<gqz<!fQIhiBl<?!ubqX!OfiGl<!
 G{<c!nm<svl<!-Vf<kiz<!Lgl<?!giz<!-ju!uQr<Gl<?!osf<fQI!
ux<Xl</!
 Olz<!uqziuqz<!ouKl<Hl<?!lzl<!sqg<Gl<!
 sqXfQI!lR<st<!fqxliGl</!
 g{<!sqX!lR<st<!gzf<K!ou{<{qxl<!ohXl</!
gilijz!ohiKg<G{l<!;< << << < !
! ! ge<ez<!olipqbe<eOl!lqe<ezqjmobe<eOl!ohie<eqe<!!
! ! ! ! ! ! ! sqlqokipk<KkeOl!
ogickie!gilijz!OviglK!%XOue<!gequqOeiM!ueqjk!OgT!
ohie<eqb!ngl<!giz<!ngl<!jggtieKl<!LgOliM!fig<G!g{<!
h,juOb!OkgLl<!ye<xib<!ouTg<GOl!jggizbIf<K!OhiGl<!
ue<eLX!Okgl<!fMg<gl<!gMg<GOl!bqjtObiM!lzl<!uxTl<!
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-kligOu!dmz<!uQr<Gl<!gjtbXl<!giK!okieq!lf<kliGl<!
-e<Elxq!dkvlqz<!fQV!gelib<!uVl<!kjzg<gel<!ofR<osiqh<H!
-klig!uibqOz!fQVxq!ucBOl!ofR<sosiqk<!Okh<hL{<mil</!
- Gl<hLeq!hizuigml<!hg<g!w{<!2:1?!himz<!w{<!867< < < < < << < < < < << < < < < < !
!
!
!
 dt<tr<giz<?!dt<tr<jg?!Lgl<?!fig<G;/!g{<[l<!lR<stqk<K!
dt<tK/!
 jg?giz<!nbIf<Kl<?!OkgLl<!ouTg<Gl</!
 Okg!fMg<gLl<?!-jth<Hl<?!lzl<!ux{<M!gm<Ml</!
 dmz<!uQr<Gl<?!giK!lf<kliGl<?!kjzg<geLl<!ofR<osiqh<Hl<?!
uib<!fQVxz<!Ngqb!GxqG{r<gt<!d{<miGl</!
- Gl<hLeq!hizuigml<!hg<g!< < << < << < <
w{<!2:1?!himz<!w{<!867< < << < << < < !
!
gilijzbqe<!<<< G{l<;<<< !
fglKl<!lzl<!fQI!fig<Gl<!fbeLl<!lR<s{qk<K!
LglK!hqxr<giz<!jggt<!LMgqTl<!uQg<gliGl<!
nglK!hmhmg<Gl<!nskqBl<!uif<kqB{<mil<!
!!!!!!!!!SglK!gi{ikiGl<!osiz<!hqk<k!gilijz!obe<Ox”!
! gilijzbqe<!G{l<;< << << < !
 gilijz! Ofibqz<! fgl<?! lzl<?! sqXfQi<! fig<G!
lR<stqk<kz</!
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 LgLl<!lR<stqk<kz</!
 Hxr<giz<?!jggt<!uQg<gl<!gi[kz</!
 hmhmk<kz<!?!nskq?!uif<kq!d{<mikz</!
!!!!!!!!!!!!!!!!!!!!!!hqk<k?nskq?<<< !OfiBl<!<<< nEhulVf<KgTl</!< << << < !!!!
- !!!!!!!PageNo:!4:/!
!
!
!
!
kQ;rs; NehT; ;; ;; ;  
gih<hie!n^<kqbqOz!$M{<migq!
! gVuie!hqk<klkqz<!uq]l<!kie<!ogi{<M!
Ofx<hie!fvl<H!upq!sqvOlz<!ogi{<M!!
! Ofvig!gzsk<Kg<Gt<Ot!kiuq!
Ogih<hig!ogikqk<K!nez<!hqk<kl<!lQxq!
! GlxqOb!ohir<gq!fQI!lR<st<!OhiOz!
Nh<hig!Ngivl<!Gjxf<K!Oleq!
! ngl<!jg!giz<!fgl<!S{<M!g{<[!hz<Zl</! ! !
!
hz<zh<hi!sqX!fQI!lR<st<!OhiOz!
! hgI!lisl<!ye<X!ujv!lR<st<!Ofiuil<!!
ouz<zh<hi!Lh<hKg<Gt<!kQviuqm<miz<!
! Ougqe<x!gilijzbkqz<!OhiGl<!g{<mib<!
fz<zh<hi!svQvolz<zil!uqtxqg<!gi[l<!
! fzoleOu!nXhKg<Gt<!kQviuqm<miz<!
nh<hOe!osr<giliiq!biGl<!g{<mib<!
! ncg<gckie<!heqOuIju!SjlB{<miGl<!!!!!!!!!!!!!!
!
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d{<miGl<!Ouupz<!Suisl<!Lm<Ml<!
! yV!Ofvl<!Ybilz<!lbg<gL{<mil<!
g{<miObi!g{<!lsUl<!hqvl<l!L{<mil<!
! jg!giZl<!dXh<ohz<zil<!ktIs<jsB{<mil<! !
uq{<miObi!uQg<gLx<X!lzUl<!sqg<gq!
! Ougqe<x!sqOzx<helkqz<!OgihL{<mib<!
kq{<miMl<!se<eqbK!OsIf<kOhiK!
! os{k<kqOz!lv{ole<X!okiGk<Ks<!osiz<Oz/! ! !
!
osiz<ZgqOxe<!lR<st<!OfiU!yV!lisk<kqz<!
! Oki]lqz<jz!sik<kqbl<!kieiGl<!g{<mib<!
fz<ZgqOxe<!gilijz!v{<mil<!lisl<!
! fibgOe!lVf<K!osb<bqz<!uqmh<OhiGl<!
nz<ZgqOxe<!osr<giliiq!&e<xil<!likl<!
! nu<]kr<gt<!osb<kiZl<!nsik<kqbliGl<!
ouz<ZgqOxe<!Gg<Gm{<m!Gpl<H!fsqbl<!
! Ougqe<x!giqsijz!w{<o{b<!GcfQI!OgT/! ! !
!
OgOt!fQ!glzigq!g]ibl<!kiEl<!
! ogcbie!vi <^eikq!ktUl<!juOb!
hiOt!fQ!lR<st<!Ofib<!hqk<kliGl<!
! utVgqe<x!gilijzbK!hqk<k!uikl<!
$Ot!fQ!sqOzx<hel<!kie<!osr<giliiq!
! kqxq!fic!&e<X!uVl<!ye<xib<!%c!
NOt!fQ!Jb!hqk<k!uikl<!kiEl<!
! nuvuIgt<!fqjz!kuxqz<!lv{l<!kiOe/!! !
! ! ! ! ! lR<st<!gilijz!OfiBl<!lVk<KuLl<!3112< < < < << < < < << < < < < !
!
ohiKg<Gxq!G{r<gt<;< < << < << < < !
okimg<g!fqjz;<<< !
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! g{<{qe<! out<jt! uqpqBl<?! nke<! hqe<! Lgl<?! gPk<K?! dmz<!
LkzqbeUl<! lR<stqg<Gl<?! fic! fjm! ktIkz<?K~g<glqe<jl! Ngqb!
GxqG{l<!-Vg<Gl</!
Lx<xqb!fqjz;<<< !
! Ofib<!Lkqv!Lkqv?!fi?!uibqe<!Olz<higl<?!dkM?!sqXfQI?!-jugTl<!
hch<hcOb!lR<st<!fqxk<jk!njmf<K!ogi{<Om!uVl</!!nke<!hqe<?!Okiz<!
lR<st<!fqxk<OkiM!hs<js!fqxl<!ohx<xK!Ohizg<!gi[l</!
kQuqv!fqjz;QQQ !
! Ofib<! kQuqvlibqe<! &g<G?! hz<zQX?! uib<! -ux<xqzqVf<K! GVkq!
uVuK{<M/!
! sqXfQI! lqgUl<! lR<stqk<K! GVkq! gzf<kix<Ohizg<! gi[l</!!
uqbIjuBl<! lR<stqg<Gl</! wV! )lzl<*! ouTh<OhiM?! GpGpk<K! -pqBl</!!
sqzIg<G!dlqp<fQI?!g{<{QI?!hz<!LkzqbjugTl<!lR<stqk<kqVh<K{<M/!
!
Ofib<!w{<;< << << < !
! hizuigml<!F~zqz<?< << << < !!
gilijz!ujg!w{<;4<<< !
2/ DK!gilijz!
3/ lR<st<!gilijz!
4/ uxt<!gilijz!
Gl<hLeq!hiuigm!F~zqz<< << << <!!
gilijz!ujg!w{<;6<<< !
2/ lif<k!gilijz!
3/ fQI!gilijz!
4/ lR<st<!gilijz!
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5/ uxt<!gilijz!
6/ hi{<M!gilijz!
dbqI!gig<Gl<!sqk<k!lVk<Ku!F~zqz<< < < < << < < < << < < < <!
! ! Gpf<jkg<G!uVl<!gilijz!< < << < << < < !ujg!w{<;4<<< !
2/ uxt<!gilijz!
3/ lR<st<!gilijz!
4/ DK!gilijz!
b,gq!juk<kqb!sqf<kil{q!F~zqz<< < << < << < <!
! lR<st<!gilijz!ujg!w{<;!24!< < << < << < < !
2/ uik!gilijz!!
3/ hqk<k!gilijz!
4/ gh!gilijz!
5/ uikgh!gilijz!
6/ hqk<k!gh!gilijz!
7/ Lg<Gx<x!gilijz!
8/ lR<st<!gilijz!
9/ npz<!gilijz!
:/ osr<glz!gilijz!
21/ Gl<h!gilijz!
22/ Ge<l!gilijz!
23/ DK!gilijz!
24/ uvt<!gilijz!
ngk<kqbi<!3111!F~zqz<!< < << < << < < gilijz!ujg!w{<;9<<< !
2/ uik!gilijz!
3/ hqk<k!gilijz!
4/ sqOzk<Kl!gilijz!
5/ hqk<k!!sqOzk<Kl!gilijz!
6/ uik!sqOzk<Kl!gilijz!
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7/ se<eqhik!gilijz!
8/ hqk<kuik!gilijz!
9/ Osijh!gilijz!
!
Nk<li!vg<<< << <<]ilqi<k!juk<kqb!sivsr<gqvgl<!F~zqz< < < << < < << < < < <;!
gilijz!ujg!w{<;6<<< !
2/ uvt<!gilijz!
3/ uik!gilijz!
4/ hqk<k!gilijz!
5/ Jb!gilijz!
6/ lR<st<!gilijz!
ke<uf<kqiq!juk<kqbl<!F~zqz<;< < < < << < < < << < < < < !
gilijz!ujg!w{<;6!<<< !
2/ uik!gilijz!
3/ hqk<k!gilijz!
4/ sqOzk<Kl!gilijz!
5/ Lg<Gx<x!gilijz!
6/ Gl<h!gilijz!
!
hizuigm!F~zqz<;<<< !
DKgilijz;!
“DKgilijzg<!G{r<gOti!B,kq!Lgr<!gizjkg<Gl<!
Hikq!sill<!hsqobMg<Gl<!Hsqk<k!UmOe!lf<kqg<Gl<!!
sQkl<!sqXk<K!ubqXuqMl<!sqf<jk!lbg<g!L{<miGl</!
giK!ljmg<G!lqjth<H{<mir<!gilijz!!
giKm!Eml<Hl<!g{<[l<!geg<gou!uQr<Gl<!ux<Xl<!
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OhikOu!fiUl<!H{<{ib<h<!ohiVf<kqb!SvL{<miGl<!
ouKjg!giZl<!Osii<f<K!ouXk<kqM!le<ef<!ke<je!!
DKgilijz!obe<Ox!Bjvk<kei<!Lequi<!kiOe”/!
DKgilijzbqe<!GxqG{l<;< << << < !
 Lgl<?!giz<?!Dkz</!
 hsq!wMk<kz<?!d{<m!dme<!lf<kqk<kz<!
 ubqX!gpqkz<?!lbg<gl<!d{<mikz</!
 giK!njmh<H?!-jth<H!d{<mikz</!!
 giK?!dml<H!?!g{<!uQr<gq!hqe<!ux<Xkz</!
 Svl<!d{<mikz</!
 jg?!giz<!Osii<kz</!
!
uvt<!gilijz<<< ; 
“g{<hs<ose<!OfbqVg<Gl<!giOzib<k<!Kml<HzVl<!
! ! k{<{Qi<g<G!olk<kk<!kuqg<Gl<!.oh{<O{!
-Vm<!hqpl<jhh<!OhiZ!lqtuZg<Gk<!kie<!Ofi<!
uvm<gilijzg<!G{k<kqe<!uiX”/!!
uvt<!gilijz!GxqG{l<!< << << < !
 g{<?!hs<js!fqxljmBl<!
 nkqg!kigl<!
 dml<H!dzi<kz<!
 jg?!giz<!Yb<kz</!!
!
Ofib<!dVuiGl<!uqkl<;< < << < << < < !
d{U!hpg<gk<kqz<!Oux<Xjlgt<;!
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! ! ! )dh<H?!Htqh<H!Sjugt<*!
npz<!Gx<xk<jk!nkqgh<hMk<Kl<!osbz<gt<!lx<Xl<!d{U!
)oub<bqzqz<!osz<zz<?!-vuqz<!g{<!uqpqk<kz<*!
!
npz<!OgM!njmkz<!
! !
hsqk<kQ!lf<kh<hMkz<!
!
Kj{big!JbLl<!Ogmjmkz<!
!
hvUgiz<!hikqh<hjmkz<!
!
d{<m!d{uqe<!sivl<!dmzqx<G!OsIukqz<!liXhiM!Wx<hmz<!!
!
GVkqbqe<!ue<jl!ogMkz<!
!
uzh<him<Cvz<!kihqkl<!njmkz<!
!
hqk<kfQI!uzh<him<CvzqVf<K!hqk<kh<!jhg<G!osz<ukqz<!liXhiM!Wx<hmz<!
!
hqk<kfQI!ke<etuqz<!lqGf<K!GVkqObiM!gzk<kz<?!)serum Bilirubin  !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
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!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!level*!
lR<st<!Ofib<!GxqG{r<gt<!Okie<xz<!
!
Lg<Gx<x!-bz<;!< < << < << < < !
! ! sqk<k.! lVk<Ku! nch<hjm! kk<Kuk<kqe<! hc! dmz<!
-br<Gukx<Giqb!dbqi<kiKg<gt<!uikl<?!hqk<kl<?!ghl<!weg<!%xh<hMl</!
! uikl<?! hqk<kl<?! Jbl<! &e<Xl<! keqk<keqOb! ke<etuqx<G! Olz<!
lQXgqe<x! gizl<! ‘sf<kq! slbl<”! we<Xl<?! lQxq! fqe<x! OhiK! ‘! hqvOgih!
slbl<”!we<Xl<! )ke<eqjz!uti<s<sq! Oux<X!fqjz!uti<s<sq! we<hK!Ohiz*!
nh<hiz<! <lVf<Kgjtg<!ogiMk<K!G{liGl<!OhiK! ‘sle!slbl<”!we<Xl<!
)nkiuK!ke<eqjzbikz<*!%Xui<!
! weOu!-l<&e<X!sg<kqgTl<!ke<!ntuqz<!osu<uOe!osbz<hMl<!
OhiK!dmz<!kiKg<gt<!Ofibqe<xq!-br<Ggqe<xe/!!!
! Utq?!npz<?!!Jbligqb!Lg<Gx<xr<gTl<!kk<kl<!-bx<jgk<!
ke<jlbqeqe<Xl<!OuXhMl<!OhiK!‘Ofib<”!weh<hMl</!hq{qg<gh<hm<m!
Gx<xk<kqeeuig!Ofibqe<!ke<jl!njlBl</!!!
! Htqh<H?!dh<H!Sju!ohiVm<gjt!-bx<jg!ntuqx<G!lQxq!wMk<Kg<!
ogit<ukiZl<?!sqz!osbz<gtiZl<!hqk<k!Gx<xl<!Ogmmjmf<K!npz<!lqG!
G{k<jkg<!gim<Ml</!
! !
nju! 
 g{<?!lzl<?!sqXfQi<?Okiz<!-jugt<!lR<st<!fqxljmkz</!
 Gjxf<k!K~g<gl<!
 dmz<!Lx<Xl<!wiqs<sz<!d{<mikz<!
 hsqbqe<jl!Ngqb!Gxqg{r<gjt!gim<Mgqe<xe/!
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! npz<!Gx<xk<jkk<!okimi<f<K!JbLl<!Ogmmjmf<K!nke<!hqe<!
uikLl<!hikqh<H!njmgqe<xe/!!!!
gilijz!Ofibqz<!hqvkielig!hikqg<gh<hMl<!hqk<kk<kqe<!fqjz;!< < < < < < << < < < < < << < < < < < < !
hqk<kl<;< << << < !
hqk<kl<!uiPlqml<;< < << < << < < !
! hqr<gjz?!hqvi{uiB?!fQi<hjh?!&zig<gqeq?!-Vkbl<?!kjz?!ogih<h,p<?!
df<kq?!-jvh<jh?!uqbi<ju?!fiuqZ~Xgqe<x! fQi<?! osf<fQi<?! sivl<?! g{<?Okiz<!
-u<uqmr<gtqz<!uiPl</!
npzqe<!-bx<jgh<< < << < << < <!h{<H;<<< !
! “hsqkigl<!yr<ogitqg{<!hii<juh{<!mk<K< < < < < << < < < < << < < < < < !
! ! Vsqokiq!sk<kqoul<jluQvl<!< < Q << < Q << < Q < .!dsqk!
! lkq%i<k<k!Hk<kqueh<!htqk<Kg<!gig<Gl<< < < < < < < << < < < < < < << < < < < < < <!
! ! nkqgiiq!bir<gi!epz</< << << < ”!
! ! ! !
npzieK?! ke<! -bx<jg! fqjzbqz<! fqe<X! osiqh<hqk<kz<?! oul<jl?!
hii<ju?!hsq?!fQi<Oum<jg?!Sju?!ytq?!fqjeh<H?!nxqU?!ue<jl?!ole<jl?!
we<hju!d{<mig<Gl</!
!
!
!
!
hqk<kl<< << << <! hqk<kk<kqe<!-bx<jg!< < < << < < << < < <
h{<H<<< !
lR<st<!gilijzbqz<!< < << < << < <
hqk<kk<kqe<!osbz<< < < << < < << < < <!
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nex<hqk<kl<< < << < << < <! fQi<ucuLt<t!ohiVjt!
uxt!osb<K!d{<m!
d{Uh<!ohiVjts<!
osiqg<Gl<hc!osb<Bl<!
hikqh<H!
)hsqbqe<jl?!osiqbjl*!
-vR<sgh<!hqk<kl<< < < << < < << < < <! osf<fQjv!lqGkqh<!
hMk<Kl<!osf<fQiqe<!
-bx<jg!ke<jljb!
hiKgig<Gl<!
hikqh<H!
)hqk<k!fQiqe<!ntUl<?!hqk<k!
fqxlqgTl<!GVkqbig!gzf<K!
nke<!-bx<jg!ke<jljb!
hikqh<hkiGl</!*!
sikgh<hqk<kl<< < << < << < <! nxqU?!Hk<kqjbg<!
ogi{<M?!uqVh<hlie!
okipqjz!fqjxOux<Xl<!
hikqh<H!
)dmx<Osii<Ul<!les<Osii<Ul<!
d{<mig<Gkz<!*!
hqvisgl<<<<! OkiZg<G!ytqjbg<!
ogiMg<gqxK!
hikqh<H!
)hqk<kfQi<!ke<etuqz<!lqGf<K!
GVkqBme<!gzf<K!lR<st<!
fqxk<jk!Okizqx<G!ntqk<kz<!
lx<Xl<!Okiz<!ux{<M!Ohikz?<!
fjls<sz<!d{<mikz</!*!
NOzisgl<<<<! g{<gtqz<!uip<f<K!
ogi{<M!wz<zi!
ohiVm<gtqe<!
ucuk<jkBl<!nxqkz<!
-bz<H!
!
!
! lR<st<! gilijzbqz<! npz<! Gx<xl<! Lke<jlbigh<! hikqg<gh<hm<M!
nk<Kme<!Jbk<jkBl<!Kj{g<ogi{<M!npjzblig!hikqh<H!njmgqe<xe/!
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lR<st<!gilijz!Ofibqz<!Kj{big!hikqg<gh<hMl<!ghGx<xk<kqe<!< < < < < < < < << < < < < < < < << < < < < < < < <
fqjz!
!
ghl<<<<! ghk<kqe<!-bx<jgh<!< < < << < < << < < <
h{<H<<< !
lR<st<!gilijzbqz<< < << < << < <!
ghk<kqe<!fqjz< << << < !
nuzl<hgl<< << << <! FjvbQvzqz<!-Vf<K!
lx<x!fie<G!
Jbr<gm<G!hx<X!
Ogimib<!-Vg<Gl<!
-bz<H!
gqOzkl<<<<! -jvh<jhbqz<!-Vf<K!
d{U?!fQi<!
Lkzqbux<jx!
=vh<hMk<kq?!
osiqh<hqg<Gl<!
hikqh<H!)osiqbijl*!
Ohikgl<<<<! fiuqeqe<X!Sjujb!
nxquqg<Gl<!
hikqh<H!)Sjugt<!
nxqbijl*!
kx<hgl<< << << <! kjzbqeqe<X!
-Vg{<gm<G!
Gtqi<s<sqjbk<!kVl<!
sqzOujt!hikqh<H!
)g{<!squk<kz<*!
!
sf<kqgl<< << << <! gQz<gjt!
ye<jxobie<X!
ohiVk<kqk<!ktv!
osb<Bl<!
-bz<H!
!
! lR<st<! gilijz! Ofibqz<! npZl<! JbLl<! hikqh<hjmf<K!
npjzbligq?! -u<uqV! Gx<xr<gTl<! lqGf<k! fqjzbqz<! hvUgijz!
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)uikk<kqe<!hqiqU*!ke<!okipqz<!fjmohxikhc!Ogmjmbs<!osb<K!GVkqbqe<!
ue<jljbBl<!ogMk<K!-f<Ofijbh<!hqxh<hqg<Gl</! !
Lg<Gx<x!OuXhiM;< << << < !
npZl<?!JbLl<!hikqh<hjmkz<!
!
uik!Gx<xLl<!hikqh<hjmkz<!
! !
Lg<Gx<xLl<!liXhiM!njmkz<!
npz<!Gx<xl<< < << < << < <! !ghg<Gx<xl<< < << < << < <! !!uikg<Gx<xl<< < << < << < <!
2/nex<hqk<kl<!
)osiqbijl*!
!
2/gqOzkgl<!)osiqbijl*! 2/hqvi{e<!)osiqbijl*!
3/!-vR<sgh<!hqk<kl<!
)osf<fQIhikqh<H*!
3/Ohikgl<)Sjugt<!
nxqbijl*!
3/!nhiee<!)lzg<gm<M?!
sqXfQI!lR<stqk<kz<*!
!
4/sikgh<!hqk<kl<!
)okipqz<gt<!hikqh<H*!
! 4/uqbiee<!)dmjzg<!
gih<hK!hikqh<H*!
!
5/!hqvisgh<!hqk<kl<!
)Okizqe<!fqxl<!liXkz<*!
! 5/dkiee<!)uif<kq*!
! ! 6/sliee<)sivk<jk!
dmzqz<!OsIh<hqk<kz<!
hikqh<H*!
!
! ! 7/%Ile<)hzl<!Gjxkz<*!
8/!gqVgve<!)uib<fQI?!
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! !
NgOu! npz<! Gx<xl<! Ogmjmukiz<! npz<! uiPlqmlie! df<kq?!
-jvh<jh?! ogih<h,p<?! osf<fQI?! fiuqZ~Xgqe<x! fQI?! sivl<?! uqbIju?! g{<?!
Okiz<!Ngqb!-u<uqmr<gTl<!hikqh<H!njmgqe<xe/!
npz<! Gx<xk<jkk<! okimIf<k! Jbg<! Gx<xLl<! Ogmjmukiz<! Jbl<!
uiPlqmlie!fig<G?!d{<{ig<G?!GVkq?!ls<js?!g{<?!ohVr<Gmz<!Ngqb!
-u<uqmr<gTl<!hikqh<H!njmgqe<xe/!
! npz<!Gx<xLl<?!Jbg<!Gx<xk<jkBl<!okimIf<K!uik!Gx<xLl<!
Ogmjmukiz<! uikl<! uiPlqmlie! nhiee<?! lzl<?df<kqbqe<! gQp<!
&zl<?Okiz<?!De<!Ngqb!-u<uqmr<gTl<!hikqh<H!njmgqe<xe/!
fic!fjm;!
! hqk<kl<! ke<!-bz<hqzqVf<K!liXhm<M! Oux<Xfqjz!utIs<sq!njmf<K!
ghk<kqjeBl<!hikqk<K?!hqe<!uiBUl<!hikqh<H!njmgqe<xe/!
hqk<kgh!fic;<<< !
! “h{<hie!hqk<kk<kqz<!Osk<Kl!fic!
! hiqsqk<ki!zk<kqSv!lqjth<H!=jt!
“g{<giK!fbelzl<!fQV!lR<st<< < Q < << < Q < << < Q < <!
! geubqX!ohiVlz<!lR<st<Ofib<!< < << < << < < g{<O{iU!
! d{<OhiK!lXk<kz<!vk<k!uqh<!HVkq!kiEl<!
djtlif<jk!hQeqsLl<!vk<k!uQg<gl<!
! f{<hie!gilijz!Osijg!ouh<H!
Dxz<?!hsqbqe<jl*!
9/!Okukk<ke<!)dmz<!
Osil<hz<*!
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! f[gquf<k!hzhq{qBl<!gi[l<!kiOe”!
- skg!fic!
okieqh<hie!hqk<kk<kqz<!sQktr<%cz<!
! okif<kqk<kiz<…//!
hir<GmOe!gilijz!Osijh!uQg<gl<!
Jbhqk<k!fic<<< !
! “-mlie!Osk<Klk<kqz<!hqk<k!fic!
! !!!!kqmlie!GtqI!gib<s<sz<!lR<st<OfiU< << << < !
! !Okgk<kq!Zjts<szqjth<!hqVlz<!uif<kq”!
! !!!!gkqh<hie!Osk<Klk<kq!Zm<c{r<!%cz<!
!Kkqh<hie=vzk<kqg<!gib<U!vk<kl<!!
- skg!fic!
hqk<k!uik!fic;<<< !
! “siElimi!hqk<k!lf<k!uikk<kq!Ozxqz<!!
! ktR<osb<Bl<!hi{<M!gilijz!kiEl<”!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!.fic!F~z<<<<!
!WP!dmx<kiKg<gt<!)nz<zK*!WP!dmx<gm<Mgt<< < < < < < << < < < < < << < < < < < <!
sivl<;!.!
 dmjzBl<?!lek<jkBl<!Dg<gLxs<!osb<uK/!!!
 lR<st<! gilijz! Ofibqz<! dmz<! ue<jlBl<! Ge<xq! leLl<!
hikqg<gh<hMl</!!nkiuK!dmx<Osii<Ul<?!leOsii<Ul<!Wx<hMl</!
osf<fQi<;.!
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 nxqU?!ue<jl?!ytq?!osVg<G?!yzq!-jugjt!fqjzg<gs<!osb<uK/!
 lR<st<! gilijzbqz<! osf<fQi<! ke<! -bx<jgbtuqz<! hikqg<gh<hm<M!
hqk<k! fQiqe<! ntUl<?! hqk<k! fqxlqgTl<! GVkqbqz<! gzf<K! nke<!
-bx<jgk<! ke<jl! hikqg<gh<hm<M! hsqbqe<jl?! lR<st<! Ofib<?!
-mh<him<Cvz<!uQg<gl<!Ngqb!GxqG{r<gjtg<!gim<Ml</!
De<;.!
 dmzqe<! dVuk<jk! nke<! okipqx<gq{r<g! njlk<kZl<?!
we<jh!uti<k<kZlil</!
 lR<st<!gilijz!Ofibqz<!De<!-bz<H!
ogiPh<H;.!
 dXh<Hgt<!gcelqe<xq!-br<g!dkUgqxK!
 nux<xqx<G!ofb<h<H!hjs!Dm<c!dkuq!HiqgqxK!! !
 lR<st<!gilijz!Ofibqz<!ogiPh<H!-bz<H/!
wZl<H;.!
 dmjz!yPr<Ghm!fqXk<kq!juk<kz<!
 dmzqe<!njsuqx<G!nch<hjmbibqVk<kz<!
 lR<st<!gilijz!Ofibqz<!wZl<H!-bz<H!
&jt;.!
 ole<jlbie!dXh<Hgjth<!hiKgik<kz<!
 we<Hg<Gt<!fqjxf<K!nux<xqx<G!ole<jlBl<?!ue<jl!kVuK/!
Sg<gqzl<< << << </SOvi{qkl<;<<< .!
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 ke<jlobik<k!dVuh<!ohVg<gqx<G!-mligqb!
gVk<Okix<xk<kqx<G!Lkzil<!fqx<hK/!
!!!!!!lR<st<!gilijz!Ofibqz<!sivl<?!osf<fQi<< < Q << < Q << < Q <!hikqg<gh<hMgqxK/!
!
!
!
!
<dmx<kiKg<gt<;< < < << < < << < < < !
!
!
!
!
w{<ujgk<OkIU< << << < !
w{<ujgk<!Oki<U!nz<zK!hq{qbxq!Ljxjl< < < << < < << < < < !
! ! ‘hq{qbxq! Ljxjl”! we<hK!dmjzh<! hq{qk<kzib! Ofijbk<!
okiqf<K!ogit<Tgqx!yPg<gl<!weh<hMl</!
uqkqBl<!yPg<gLl<;< < << < << < < .!
dmZl<?!
leLl<!
OsiIU!
njmkz<*!
)GVkqbqe<!
ue<jl! ogm<M!
hqk<kfQVme!
<gzk<kz<*!
-bz<H!
!
!
<!
-bz<H! !-bz<H! !!-bz<H! -bz<H!
rhuk;;;; nre;ePH; P; P; P
  
Cd;;;;
  
nfhOg;G;;;  vYk;G;;;
  
%is
  
Rf;fpyk; ; ;; ;; ; / 
RNuhzpjk;;;; 
  
38 
 
! ! -K?!
2/ ohixqbix<Oxi<kz<!
3/ Hzeizxqkz<!
4/ uqeikz<!
!
!
!
!
lR<st<!gilijzbqz<!Ofibitqg<G!gi[l<!GxqG{r<gt<< < < < < < << < < < < < << < < < < < <!
2/ ohixqbiz<!nxqkz<;< << << < !
&g<G!.!! -bz<H!
fi! ! .!! fiuqe<!nc?!dt<fig<G!!
lx<Xl<! n{<{ig<G?! lR<stqk<K!
gi[kz<!
! ! ! g{<! ! .! g{<{qe<!out<jt!uqpqBl<?!!
!!!!!!!!!!!!!!!!!!!!!!!!!!lR<stqk<K!gi[kz<!
! ! ! Okiz<!! .! OkizieK!lR<st<!fqxljmf<K?!!
!!!!!!!!!!!!!!!!!!!!!!!!!!ux{<M!fjls<sjz!d{<mikz<!
! ! ! osuq!! .! -bz<H!
!
3/ Hzeiz<!nxqkz<;< << << < !
ytq! ! .! dmzqe<!fqxl<!lR<stqk<K!!
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gi[kz<!
! ! DX!! ! .! ouh<hlig!gi[kz<!
! ! Yjs!! ! .! -bz<H!
! ! Sju!! ! .! fi!jgk<kz<?!sqz!Oujt!!
Sju!okiqbijl!gi[kz<!
! ! fix<xl<! ! .! -bz<H!
!
!
!
uqeikz<;<<< .!
!
! uqeikz<! we<hK! Ogm<mxqkz</! ! lVk<Kue<! ke<je! Ofig<gq! uf<k!
hq{qBx<xujeh<! hx<xq! nxqb! Ou{<cbux<jx! nxqf<Kl<?! ke<! ohixq!
Hze<gtiz<! hq{qbituEjmb! ohixq?! Hze<! upqbib<! d{i<ujk?!
hq{qBx<xueqmk<kqOzi!nz<zK!nue<! ohx<Oxii<?! Sx<xk<kijvg<! ogi{<Omi?!
nueK! ohbi<?! ubK?! kqj{?! GMl<h! uvziX?!d{U?! hpg<g! upg<gl<?!
Lf<jkb! Ofibqe<! uvziX?! yu<uijl! uvziX! Ohie<xux<jx! nxqkjzh<!
hx<xqbK!NGl</!
w{<ujgk<!Oki<Ugtiue< < << < << < < !
! ‘fich<hiqsl<!fifqxl<!olipquqpq!
! lzl<!Lk<kqvlqju!lVk<Ku!viBkl<” 
        .Okjvbi<!
 fi!
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 fqxl<<<<!
 olipq!
 uqpq!
 lzl<<<<!
 &k<kqvl<< << << <!
 ^<hiqsl<< << << <!
 fic!
fic;!
“fichm!hiqsl<!fifqxl<!olipq!uqpq!
lzl<!&k<kqvju!upq!fiuqVlzl<!jgg<Gxq!!
olb<g<Gxq!fqxf<okieq!uqpq!fiuqVlzl<!jgg<Gxq”/!
Ofib<fimz<higl<< < << < << < <.2!
“dmzqz<! dbqi<! kiqk<kqVh<hkx<G! giv{lie! sg<kq! wKOui! nKOu! fic!
nz<zK!kiK!NGl<”!
 ‘Gxqbib<!uzg<gvr<!Guqf<k!ohVuqvz<!!
! !uxqbi!bke<gQp<!juk<kqb!&uqvz<!
! !hqiquib<!OlOzxqh<!ohzk<kK!uiklil<!
! !nxquib<!fMuqv!zli<f<kK!hqk<kOl”!
! !‘hqk<kk<kqe<!gQOp!Hv{<m!jkblil<”!
!!!!!!!ohVuqvz<! hg<glig!l{qgm<Mg<G!yV!nr<gzk<kqx<G! Olz<!Njv!
we<hqe<!OlOziMl</!!fic!fvl<H!-vk<kg<!Gpibqe<!Olz<!&e<X!uqvz<gjt!
juk<Ks<!sx<X!nPk<kqBl<!kti<k<kqBl<!hii<g<g?!!
 Nt<gim<c!uqvzigqb!Lkz<!uqvzqz<!d{i<uK!uikl<!weUl<?!
 fMuqvzqz<!d{i<uK!hqk<kl<!weUl<!
 ohtk<kqv!uqvzqz<!d{i<uK!ghl<!weUl<nxqbUl<!
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“n{<cmOu!kiqk<kqvi<gt<!uqVk<ki<!hizi<!!
ne<higk<!k{<{Qiqz<!Lp<gqOeii<gt<”!
! ! ! ! .Ofib<himz<!higl<!2!< < << < << < < [skg!fic] 
!
!!!!!we<hke<! &zl<! sqXui<gTg<G! fic! fjm! siqbig! g{qg<g!
LcbiK! we<hK! uqtr<GgqxK/! fich<hii<g<Gl<! Le<! gjmhqcg<g!
Ou{<cb! uqkqgjt! hizi<gTg<G! nEsiqg<g! gceliekiz<! fic!
&zl<!Ofijb!siqbig!g{qg<gLcbiK/!
!
weOu!ficjb!Lke<jlbig!ogi{<M!sqXui<gTg<G!Ofijb!
fqkieqg<g! Lcbikkiz<! fQi<g<Gxq?! ofb<Gxq! Nb<uqje!Lke<jlbig!
ogi{<M! uik! hqk<k! gh! dbqi<kiKg<gjt! Dgqk<K! nke<!
nch<hjmbqz<! lR<st<! gilijz! Ofijb! g{qk<K! nkx<gie!
lVk<Kul<!Olx<ogit<th<hm<mK/!
!
! Neiz<! ohiKuig! -f<Ofibqz<! hqk<k! gh! ficBl<! gh! hqk<k!
ficBl<!gi{h<hMgqxK/!!
!
fic;!
hqk<kgh!fic?!ghhqk<k!fic/!
^<hiqsl<;< << << < !
lqkouh<hligOui?! nz<zK! nkqgouh<hligOui! nz<zK!
-bz<higOui! gi{h<hMl</! ! gz<zQvOzi! nz<zK! l{<{QvOzi! uQg<gLme<!
utIs<sq!njmkz<!nz<zK!-v{<Ml<!uQg<gLme<!uti<s<sq!njmkz<!nz<zK!
-bz<higUl<!-Vk<kz</!
fi;!
fiuqe<! nc! lR<stqk<Kl</! SvLl<! uif<kqBl<! -Vg<Gl<! gizr<gtqz<!
fiuqe<!Olx<Hxl<!ouTk<Oki!nz<zK!lih<!hcf<kK!OhizUl<!nz<zK!sqz!
  
42 
 
slbr<gt<!-bz<higUl<!gi{h<hMl</!!uib<fQVxz<?!Sju!! okiqbijl!
Ngqb!GxqG{Ll<!oke<hMl</!!
fqxl<;<<< !!dmz<!lR<stqk<K!gi[kz<!
olipq;!!
-bz<higUl<!-z<zK!uif<kq!lx<Xl<!Svl<!-Vg<Gl<!gizr<gtqz<!
sqzslbl<!kip<f<k!yzqbigUl<!-Vg<Gl</!
uqpq;!
g{<{qe<!out<jt!uqpqbieK!lR<stqk<K!gi{h<hMl</!!
lzl<;<<< !
lzlieK!-XgqBl<?!sqzOujt!ouTh<higUl<?!sqzOujt!gtql{<!
fqxligUl<!lzl<!gpqkz</!
&k<kqvl<;< << << < !
nmI!lR<st<!fqxligh<Ohikz</!
lR<st<!Ofibqe<!fQIg<Gxq!ofb<Gxq!fqs<sbk<kx<Giqb!fQI!-zg<g{l<;< < < Q < < < < < Q < << < < Q < < < < < Q < << < < Q < < < < < Q < < !
“kqmLX!hqk<kR<!sx<X!
squh<HlR<!st<Ohiz<!gi[l<!
Hjmlqgs<!squh<H!lR<st<!
Ohie<xqcx<!gilijz!biOl”!
! squh<H! lR<st<! fqxlibqe<! hqk<kOfib<! we<Xl</! lqg<g! osl<lR<st<!
fqxlibqe<!gilijz!Ofib<!we<Xl<!nxqf<Kg<!ogit<g/!
gilijz!Ofijbk<!kVl<!fQi<!fqxl<< < Q < << < Q < << < Q < <!
! ! “uie<lQg!olpqx<g{<!jlg<G{!LxqeK!
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!kie<!gilijz!Ofib<!kVl!kqe<oxeqz<!
!hqk<k!OfiObEl<!hqxg<gh<!h{qg<GOl”!
! Gr<Glh<h,!fqxk<Kt<!gVjl!fqxl<!Okie<Xlieiz<!nf<k!fQI!gilijz!
OfiobEl<!hqk<k!Ofijb!d{<mig<Gl</!
gilijz!fQI!Fjxbqe<!fqxl<Q < <Q < <Q < <!
“nf<Fjv!uQk<!gVl<!osl<jl!
!le<E~X!fqxk<kiqe<!uVr<gilijzobe<”!
! Fjv! ohiVf<kqb! sqXfQiqz<! lR<st<?! gVjl?! osl<jl! fqxr<gjtg<!
gim<Mlieiz<!gilijz!Ofib<!we!nxqbzil</!
hqk<k!gilijz!fQI!fqxl<;< Q << Q << Q < !
“lf<kqiq!fqxlib<!uvh<hM!fQVl<!
!df<kqb!wVjujb!yk<KV!fQVl<!
!hqk<Kgilijzgtiz<!hqxf<keoues<!
!sqk<kqb!uqk<kqbikvl<!lKosh<HOl”!
! hqk<k!)lR<st<*!fqxlib<!-pqgqe<x!fQVl<?!kt<th<hm<m!dkqvk<jk!yk<K!
-xr<Ggqe<x! fQVl<! hqk<k! gilijz! Ovigr<gtiz<! hqxf<keoue<X!
“uqk<kqbikvl<”!we<El<!F~z<!%XgqxK/!
fQI!ofb<g<Gxq!sqxh<H;Q < < <Q < < <Q < < < !
“hq{qBt<OtiI!fQjv!Wx<Xh<!
ohiPKLe<!juk<k!hqe<eI!
K{qUX!KVl<hq!ou{<o{b<!
Okib<okiV!KtqOb!uqm<miz<!
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n[gqfQIh<!hil<hqx<G!gi{qe<!
neqzOfib<!um<mlibqe<!
k{quqzih<!hqk<k!Ofibif<!
kr<GLk<!jkb!OfiOb”!
! uqcbx<!gizk<kqz<!hcg!hik<kqvk<kqz<!fQjv!NuqOhigikhc!ohib<k!4!
¾! fipqjgg<Gt<! nke<! fqxg<! GxqjbBl<?! hqe<! sqXfQiqz<! yV! sqxqb! Ktq!
w{<o{b<! fMuqz<! jgbjsuqeiz<! w{<o{b<! Ktq! sqkxilz<! uqm<M!
oub<bqzieK! nf<fQiqz<! hMl<hc! kqxf<K?! gix<xieK! nkqz<! uQsq! nf<k!
w{<o{b<k<! Ktq! Nmikhc! juk<K! hqe<! ns<sqXfQiqz<! uqmh<hm<cVg<gqe<x< Q < < < < << Q < < < < << Q < < < < < !
w{<o{b<!KtqbieK< << << < !Olikqvl<!Ohie<X!-jmuqm<m!um<mlibqVf<kiz<!hqk<k!< < < < < < << < < < < < << < < < < < <
Ofib<!<<< wek<!okiqf<Kg<!ogit<tzil</!
!
hqk<kl<!we<El<!npz<!fQI!ofb<g<Gxq;< < < < < Q < << < < < < Q < << < < < < Q < < !
“Npq!Ohix<hvuqe<!n0Ok!hqk<kl<< < < << < < << < < <”!
! NgOu! lR<st<! Ofibqz<! hqvkielig! hqk<k! Gx<xl<! hikqg<gh<hm<M!
nkjek<! okimIf<K! gh! Gx<xl<! hikqg<gh<hMl<! we<hjk! fic! lx<Xl<!
fQIg<Gxq!ofb<Gxqbqe<!&zl<!oktqUhMk<KgqOxe</!
utqbqe<!-bx<jgh<!h{<H;< < < << < < << < < < .!
! ! ‘yPr<Gme<!kiOkp<!&s<!Osir<gq!-br<g!
! ! ! wPs<sqohx!wh<h{qBlix<x!.!wPf<kqiqb!
! ! !Ougl<!Hze<gTg<G!Olus<!SXSXh<H!
! ! ! uigtqg<Gl<!lif<ki<g<G!uiB”!
! !
!!!!!!!-bx<jg! fqjzbqz<! fqe<X?! Dg<G! L{<mig<gz<?! &s<Suqmz<?!
uir<gz<?! leolipq! olb<gTg<G!osbjzk<kvz<?! lzl<!Lkzqb!hkqeie<G!
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uqjvUgjt! outqh<hMk<kz<?! WP! dmx<gm<Mgt<! lx<Xl<! Jl<ohixqgTg<G!
ue<jl!ogiMk<kz<!Ngqb!osbz<gjth<!HiqBl</!
! uikl<<<<! uikk<kqe<!-bx<jg!h{<H< < < << < < << < < < ! lR<st<!gilijzbqz<!!< < << < << < <
gi{h<hMl<!fqjz< << << < !
hqvi{e<<<<! &s<Suqmz<?!&s<S!uir<gz<?!
d{jus<!osiqh<hqk<kz<!
hikqh<H!)osiqbijl*!!
nhiee<<<<! lzszk<jkk<!kt<Tl<?!
ne<esivk<jks<!Osi<h<hqg<Gl<!
hikqh<H!)lzs<sqg<gz<?!
sqzOujt!gpqs<sz<?!
dmz<!ue<jl!Gjxkz<?!
sqXfQi<!lR<stqk<kz<*!
uqbiee<<<<! dXh<Hgjt!fQm<m?!lmg<g!
osb<Bl<?!dmz<!sivk<jk!
fqvh<hqk<K!dmjzg<gig<Gl<!
hikqh<H!
)dmz<!ue<jl!
Gjxkz<*!
dkiee<<<<! d{uqe<!sivk<jkg<!%cbqVf<K?!
njk!nr<gr<Og!fqXk<Kl<?!
njk!outqh<hMk<kqBl<?!
gzg<gqBl<!uVkz<!osb<Bl<!
hikqh<H!)uif<kq*!
sliee<<<<! lx<x!uiBg<gjt!lqR<s!
ouim<milz<!lmg<gqs<!
siqh<hMk<Kl<!!
hikqh<H!)sivk<jk!
dmzqz<!Osi<hqk<kz<!
hikqh<H*!
fige<<<<! wz<zi!gjzgjtBl<!gx<Gl<hc!
osb<Bl<!g{<!-jlg<Gl<hc!
osb<Bl<?!fz<z!h{<gjth<!
hiMuqg<Gl<!
Ofib<!fqjz!
nkqgiqk<kiz<!hikqh<H!!
)hck<kz<?!uqjtbimz<!
Ohie<x!osbz<gjt!
osb<b!sqvll<*!
%i<le<< << << <! ogim<miuq!uqmh<h{<[l<?!g{<! hikqh<H!)hzl<!Gjxkz<*!
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kqxg<g?!&m!osb<Bl<?!g{<{Qi<!
uqph<h{<[l<?!hzk<jk!d{<M!
h{<[l<!
gqVgve<<<<! fiuqx<gsqU?!fisqbqx<!gsqU?!
Kl<lz<?!-Vlz<!d{<mig<Gl<?!
lqg<g!hsqjbd{<mig<Gl</!
hikqh<H!
)hsqbqe<jl?!uib<!fQi<!
Dxz<*!
Okukk<ke<< << << <! Osil<hjzBl<?!dmz<!
Lxqk<kjzBl<!d{<mig<Gl<!
g{<j{!hz!-mr<gtqz<!Ym<c!
dziuqg<Gl<!
hikqh<H!!
)!dmz<!Osii<U*!
keR<osbe<< << << <! -xf<Kuqce<!gix<oxz<zil<!
outqh<hm<m!hqe<ei<!&e<xiuK!
fitqz<!kjz!ouck<k!hqe<!
kie<!OhiGl<!
!
!
.!
!
!
!
!
!
!
Jujg!fqzr<gTl<!hq{qgTl<< < << < << < <!
 “dzl<!lQtq!le<duilf<kqiq!
!dktiiqml<!dxOu!dl<hvieqml<!osie<&ui<!
!dr<Gzi!oui{<{ikOk!djlbqmli!ljk!
!dR<osi{iK”/!
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! ! ! !.sqk<k!lVk<Kuir<g!SVg<gl<< < < < << < < < << < < < <!
2/ GxqR<sq!fqzl<;!< << << < !
 -kqz<!usqh<hui<gTg<G!-vk<kk<jk!dxqR<Sgqe<x!SvLl<?!
ubqx<xqz<!Njlg<!gm<cBl<![=vz<!gm<c< << << < ] d{<miGl</!!
3/ hijz!fqzl<;<<< !
 uik?!hqk<k?ghl<!Ngqb!Lg<Gx<xl<!hikqg<gh<hm<M!Ofib<gjt!
d{<miGl</!
4/ Lz<jz!fqzl<;< << << < !
 hqk<k!Ofib<?!uik!Ofib <?=vz<!Ofib<gTl< < << < << < < <!d{<miGl</!
5/ ofb<kz<!fqzl<;< < << < << < < !
 uikOfib<!lx<Xl<!=vjzh<!ohVg<Gl<< < << < << < <?!Gmjz!hx<xqb!
Gmz<uiBjuBl<!d{<miGl</!
6/ lVk!fqzl<;!
 Lg<Gx<x!Ofib<gTl<!G{liGl</!!
!
gizl<!ohiPK<<< ;!
gizk<kqe<! ujggjtg<! ohiVk<K! lg<gtqe<! ke<jlgt<! liXhMl</!
-keiz<!wtqkqz<!Ofijbg<!g{qg<g!WKuiGl</!
gizk<jk!NX!hGkqgtigh<!hqiqg<gzil</!
2/ gii<gizl<![ljpgizl<]! .Nu{q?Hvm<misq[osh<ml<hi<?!Ng <^m<]!
3/ %kqi<gizl<![Gtqi<gizl<]! .Jh<hsq?!gii<k<kqjg![Ng<Omihi<.ful<hi<]!
4/ Le<heqg<gizl!< ! .lii<gpq?!jk![csl<hi<?!\euiq]!
5/ hqe<!heqg<gizl<! ! .lisq?!hr<Geq![hqh<vuiq?!lii<s<]!
6/ -tOueqz<!gizl<!! ! .sqk<kqjv?!jugisq![Wh<vz<?!Ol]!
7/ LKOueqz<!gizl<!! ! .Neq?!Nc![\Qe<?!\Qjz]!
!
gilijz! Ofib<gt<! nkqglig! gii<gizl<! lx<Xl<! %kqi<gizk<kqz<!
d{<migqe<xe/hqk<klieK! gii<gizk<kqz<! ke<eqjz! uti<s<sqBl<!
%kqi<gizk<kqz<! Oux<X! fqjzjbBl<?! Le<heq! gizk<kqz<! ke<eqjzBl<!
njmgqe<xe/!!
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%kqi<gizk<kqe<!G{l<< < < << < < << < < <;!
“Nkue<!gMhgz<!nmvr<!ohipqb!
Uil<lqG!heqh<Ht!fqsqBl<!uPuii<g<!
%kqove<Xjx!ohiP!kpx<Gx<x!olPr<!
OgihLx<!xqMLer<!Gtqjvs<!sgqg<gs<!!
Sikgl<!hzUjmb!leqki<g<!ogElil<!!
Kiuqzi!lVk<Ku!ohVF~z<!npzqe<!
Ogikxh<!Hiqf<kqm!ngx<XR<!sqgqs<js!
Ogit<ogeh<!Hgz<u!ohxOz!fzqe/”!
!
!outqOb!d{<mie!Gtqjvk<!kir<gqg<!ogit<Tl<!u{<{l<!dmzqe<!
dm<S,M! Okizqz<! ose<X!yPr<G!hMk<Kl<!giv{k<kiz<!dmjzg<!gig<Gl<!
Ng<gez<! [smvig<gqeq]! GjxUhMl</! Nke<! giv{lig! utqLkzib<!
%xh<hm<m!Lg<Gx<xr<gTl<!fz<z!fqjzbqz<!fqx<giK/!
!!
gii<gizg<! Gtqi<s<sqbqz<! hpg<gLx<x! Gtqi<f<k! dmZjmbui<gt<?!
%kqi<gizs<! S,iqb! ouh<hk<kiz<! fQi<! Oum<jgbjmb! OfiqMl</!Nkziz<?! gii<!
gizk<kqz<!ke<eqjz!hqxp<f<K!lqGkqh<hm<M!fqx<g!OfiqMl</!gii<gizl<!lx<Xl<!
%kqi<gizk<kqz<! hqk<klieK! -bx<jg! h{<hqzqVf<K! OuXhiM! njmf<K!
lR<st<!gilijzjb!Ofijb!d{<mig<Ggqe<xK/ 
Sju;!
Sju! nch<hjmbqz<! lR<st<! Ofibqz<! hqvkielig! Gx<xl<! njmf<k!
hqk<kk<jk!slh<hMkkq!ke<eqjzh<!hMk<kz<!!
!
!
!
hqk<k!Gx<xk<jk!nkqgh<hMk<Kl<!Sjugt<;< < < < < < << < < < < < << < < < < < < !
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Htqh<H! hqVk<uq!+!OkB! ! hqk<kl<!
dh<H!! nh<H!+!! OkB!! hqk<kl<?!ghl<!
hqk<kk<jk!sle<!osb<Bl<!Sjugt<< < < < < << < < < < << < < < < <!
KuIh<H! utq!+ hqVk<uq!
jgh<H!!!!utq!!+!outq!
-eqh<H!!!!hqVk<uq!+ nh<H!
“hqk<k!lkqgiqh<hqe<!OhSl<!hiqgivl<!
Sk<kk<!KuOviM!osiz<zqeqh<Hs<!sk<kiGl<!
jgh<Hs<!SjuOb!gVKuke<!uQX!
wb<h<!HjmB!ole<Xjvk<!kiiqr<G”/!
.Ofib<!fimz<!higl<< < << < << < <.2!
hqk<kk<jk!slh<hMkKl<!Sjugt<;!< < < < << < < < << < < < < !
-eqh<H!Sju;<<< !
“gizpz<!fs<Sr<!gckgx<Xl<!=jtBl<!!
!Sizg<!GVkqBpqp<!gisOfi.!bizuk<jk”!
-eqh<H! SjubieK! hqk<kk<jkBl<! uikk<jkBl<! fR<Sgtqe<!
ke<jlBl<!lqg<g!uqjvuqz<!fQg<Gl<//!
jgh<hqe<!osb<jg;< < << < << < < !
‘hqk<k!jlb!uqgx<hr<!
Uib<fQVvz<!npx<sqBf<!k{qg<Gl<”!
hqk<kk<kqe<! kQb! liXkz<gTl<! ghk<kqe<! kQg<Gx<x! lix<xr<gTl<?!
Gmzqz<! d{<miGl<! HPg<gTl<?! Gm<mh<! hq{qgTl<?! uib<! fQi<h<ohVg<Gl<?!
lqg<g!S,Ml<!k{qf<kqMl</!
!
!
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Kui<h<H!Sju;< << << < !
GVkq!Sk<kq!big<Gl<!
ogicb!hqk<kl<!lix<Xl<”!
/ohiz<zi!jubl<!lix<Xl<;” 
 -vk<kk<jks<!Sk<kqbjmbs<!osb<Bl<!
 ghOkimk<jkh<!Ohig<gq!uqMl</!
 hqk<kl<!ogm<cVf<K!lqg<g!Ke<hl<!uqjtuqg<Gl<!Ofijbh<!Ohig<Gl<!!
!
gii<h<H!Sju< << << < !;!
“fx<hsq!b,g<gq!fjugjth<!Ohi<ggqfi!
!Uqx<gsq!uig<gqs<!Sjubxq!uqx<he<e!
!vig<gq!b,{<sQv{l!kig<gqbir<”!
!
gii<h<hqe<!osb<jg!< < < << < < << < < < !
d{<m! d{U! ujtObiM! fqbkqh<hc! sQv{ligilz<! nkeiz<!
ubqx<xqz<!lqGl<!uiBuiz<!ubqx<xqz<!Dkjzk<!kVl</!Ngm<M!uiBh<!
hq{qBl<! OgM! uqjtuqg<Gl<! Osijg! we<El<! GVkq! Ge<xqbkiz<!
gi{l<!olb<!uQg<gl<!hq{qjbBl<!kQi<g<Gl</!
!
lR<st<!gilijz!Ofib<g<G!giv{lie!hqk<kk<jk!slh<hMk<k!-eqh<H?!
Kui<h<H?!jgh<H!Sjugjtg<!ogiMg<g!Ou{<Ml</!!
!
!
!
!
!
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!
!
giqszir<g{<{q!< << << <
$v{l<<<<!
!
Sjugt<<<<! osbz<gt<< << << <!
giqsijzs&zl<! jgh<H! jgh<H!.!hqk<kl<!lx<Xl<!!ghk<kqe<!!
Gx<xr<gjtk<!ke<eqjzh<hMk<Kl<!
gMg<gib<! KuIh<H! !
!
!
-eqh<H?!KuIh<H/!jgh<H!Sjugt<!
- hqk<kk<jkk<!ke<eqjzh<!hMk<Kl<!
!
nkqlKvl<! -eqh<H!
sQvgl<! -eqh<H?!giIh<H!
gVR<sQvgl<! jgh<H!
kie<xqgib<! KuIh<H!
lvlR<st<! jgh<H!
lqtG! jgh<H?!giIh<H!
&g<gqxm<jm! jgh<H!
ofz<zqux<xz<! KuIh<H?!-eqh<H?!
Htqh<H!
Wzl<! giIh<H! giIh<H!.!
!!!!!hsqjbk<!K~{<c!d{<m!d{ju!!!
!!!!!osiqh<hqg<gs<!osb<K!!!!
dmx<!Gx<xr<gjt!fQg<Gl</!
Sg<G! giIh<H!
kqh<hqzq! giIh<H!
kitqshk<kqiq! giIh<H!
ogik<klz<zq! giIh<H!
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“kQ;;;;st<!gilijzbqz<!nsik<kqb!GxqG{r<gt<;< < < < << < < < << < < < < !
!nkqsivk<Kme<!gilijzBl<!OsIf<K{<mikz<< < < < < << < < < < << < < < < <!
 “lR<st<Ofib<!GjzOfiU!hbqk<kqb!Ovigl<!
!DeiGl<!uVlqmk<kqz<!nkqsivr<gt<!
!!!d{<migqz<!nsik<kqbli!LXkq!kiOe”!
- skgfic!
“nkqfQOv!gilijz!biehq{q!kl<L!
!tkq!sivli!gikxq”!
.g{<[silqbl<< << << <!
!
!
-jth<HmOe!Suisl<?!uqg<gz<!-ux<Xme<!gilijzBl<!Osi<f<K!d{<mikz<< < < < < < < < < < << < < < < < < < < < << < < < < < < < < < <!
“uqmhigf<!kqvt<hi{<M!Osijggi!lijz!
!hGk<kqmm!-jth<HmOe!Suisl<!uqg<gz<!
!hx<xqeiz<!lv{ole<X!hGk<Ks<!osiz<Oz”!
- g{<[sil<<< qbl<<<<!
gilijzBme<!ubqx<X!djtUl< << << < <!Osi<f<K!d{<mikz< < < << < < << < < < << <<!
“uQxie<!Ge<llk<!Svr<gi!lijz!
/! ! !uz<zjlbi!bqf<Ofibqz<!ubqx<X!jts<sz<!
!/uf<k[gqz<!lv{ole<X!useqh<H!hiOb”!
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!
!
!
nsik<kqb!GxqG{l<!;< << << < !
 nkqsivk<Kme<!gilijzBl<!Osi<f<K!d{<mikz<!
 -jth<HmOe!Suisl<?!uqg<gz<!-ux<Xme<!gilijzBl<!Osi<f<K!
d{<mikz<!
 gilijzBme<!ubqx<X!djtUl<!Osi<f<K!d{<mikz<!
.!g{<[silqbl<< << << <!
 sqXfQI!lR<stqk<K!Gpl<H!Ohiz<!outqObXkz<!
 &g<G!uisje!okiqbilz<!-Vk<kz<!
 -Vkb!hikqh<H!Wx<hmz<!
 Hxr<giz<?!Lgl<?!dmz<!uQg<gl<!gi{z<!
 dmz<!LPuKl<!Lc!dm<hm!gpx<sqg<gib<!fqxlib<!-Vk<kz</!
.!b,gqLeq!
lVk<Ku<<< Ljx;!!
! ! ! “ulek<kiz<!hqk<kl<!kiPl<< < < < << < < < << < < < <”!
! -g<%x<xqe<hc! npz<! Gx<xk<jkk<! ke<eqjzh<hMk<k! Okjuh<hce<!
lm<Ml<! uif<kq! osb<uqg<g! Ou{<Ml</! Neiz<! Ofibitqgt<! Gpf<jkgtig!
-Vh<hkiZl<?! OlZl<! -f<Ofibqz<! uif<kq! -Vh<hkiZl<! -kje! osb<uqg<g!
Ou{<cb!nusqbl<!-z<jz/!hqe<!hsqk<kQjbk<!K~{<cm!%cb!lVf<Kgt<!kv!
Ou{<Ml</! ! lqGf<Kt<t! hqk<kfQjv! outqObx<xg<! %cb! lVf<KgTl<!
ogiMk<K?! -vk<kk<kqe<! ue<jljbh<! ohVg<gg<%cb! nbs<sk<Kt<t!
lVf<KgjtBl<?=vz<!Okx<xq!lVf<KgjtBl<!upr<g!Ou{<Ml</!
gilijz!OfibitqgTg<gie!d{ULjx;<<< !
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gVl<Hs<siX?! LVr<jgg<gQjv! gR<sq?ou{<jmg<gib<! Gpl<H?! -tfQI?!
-m<zq?!Kuvl<hVh<H?!hs<js!hbX!OsIk<K!Gjpb!juk<k!sikl</!
!
!
!
!
hqk<kk<jks<!slh<hMk<Kl<!ohiVt<gt<< < < < < < < << < < < < < < << < < < < < < <!
olis<js!Smjz!ohiVLx<gTPf<!Okzouf<kq!
ols<S!lqtGS{<jm!ou{<o{bqR<sq!hs<jsfqxr<!
gim<Mlh<jhg<!Ogiju!gVfql<hl<!sQvgr<gt<!
%m<Mg<gxq!hqk<ksll<!%X/!
!
d{<{g<%mikjugt<;< < << < << < < !
2/ ouh<h!G{Ljmb!hkiIk<kr<gt<!
3/ ogiPh<H?!w{<o{b<!ujggt<!
4/ $M!lixik!d{U?!lQe?!</lilqsl<?!Lm<jm!!
5/ dh<H!lqgg<!GjxuigOui!nz<zK!hbe<hMk<kilz<!-Vh<hK!
fz<zK!
6/ gih<hq!Osi<f<k!ujggt<!
-  
- kQ;rs; Neha; epjhdk;.; ; ; ;; ; ; ;; ; ; ;  
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MODERN ASPECTS 
 
                    lR<st<!< << << < gilijz!
 
MODERN ASPECT 
Liver 
Anatomy 
Synonym 
 Hepar (the term hepatic) 
Definition 
 Liver is the largest gland in the body. 
 Situated in the right upper quadrant of the abdominal cavity 
 Most of it is covered by the ribs and costal cartilages except in the upper 
part of the epigastrium. 
Location 
 It occupies in the right hypochondrium, greater part of the epigastrium 
and extends in to the left hypochondrium upto the left lateral line. 
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Shape 
It is wedge shaped. It resembles a four sided pyramid laid on the one side 
with its apex directed towards the left. 
Colour 
 Reddish brown 
 Soft and very friable 
 
Weight 
 In foetus - 1/25 of  body  weight 
 In adult - 1/40 of  body  weight 
          1400  -     1800 grams in males   
          1200  -  1400grams in females 
 A range of 1000- 2500 gram. 
 
External Features 
 Mainly it has two surfaces. 
1. Diaphramatic (in contact with the diaphragm) 
2. Visceral (in contact with several abdominal viscera) 
 
Diapharamatic surface 
 It is bodly convex, molded to the under surface of the diaphragm. It is 
subdivide into. 
  
58 
 
1. Anterior 
2. Posterior 
3. Superior 
4. Inferior 
5. Right 
 
The inferior surface is well defined because it is demarcated by the 
sharp inferior border. 
 
Visceral surface 
 It is flat and slopes downwards forwards and to the right from the 
posterior surface. 
There is no clear dividing line. 
One Prominent border 
 The inferior border is prominent border 
 It is sharp anteriorly 
 It separates the anterior from the inferior surface 
 It is laterally rounded, it separates the right from the inferior surface. 
The sharp anterior part is marked by 2 notches 
i) inter lobar notch,  
ii) cystic notch 
i) inter lobar notch 
The notch of  ligamentum teres. 
ii) Cystic notch 
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a. The fundus of the gall bladder. 
in the epigastrium the inferior border extends from the left 8th 
costal cartilage to the the right 9th costal cartilage. 
b. Other borders are rounded and ill defined. 
 
Lobes 
 Liver is divided into the 2 lobes 
 Right lobe 
 Left lobe 
Right Lobe 
 It is larger 
 5/6 Part of liver 
It has 2 additional lobes 
i) caudate lobe 
ii) quadrate lobe. 
 
It connects the right lobe of liver by the caudate process. Below and left it 
presents as small rounded elevation called the papillary process. 
Portal hepatis 
 It is a deep transverse fissure 
 situated in the inferior surface of the right lobe of the liver it is 
between 
Above  - caudate lobe 
Below - quadrate lobe 
Left lobe 
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 It is smaller. Only 1/6 part of liver 
 It is flattened 
 Its inferior surface is near the fissure for ligamentum venosum. 
A rounded elevation called the omental tuberosity (tuber omentale). 
 
 
 
 
 
 
 
LIVER 
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PHYSICOLOGY OF BILE PRODUCTION AND FLOW: 
Bile Secretion and Composition Bile formed in the hepatic lobules is 
secreted into a complex network of canaliculi, small bile ductules, and larger 
bile ducts that run with lymphatics and branches of the portal vien and hepatic 
artery in portal tracts situated beween hepatic lobules. These interlobular the 
right and left hepatic ducts which in turn unite to from the common hepatic 
duct. The common hepatic duct is joined by the cystic duct of the gallbladder to 
from the Common Bile Duct (CBD) which enters the duodenum through the 
ampulla of vater. 
 Hepatic bile is an isotonic fluid with an electrolyte composition 
resembling blood plasma. The electrolyte composition of gallbladder bile differs 
from that of hepatic bile because most of the inorganic anions chloride and 
bicarbonate have been removed by reabsorption across the gallbladder 
epithelium. As a result of water reabsorption total solute concentrate of bile 
increases from 3 to 4 g/dL in hepatic bile and 10 to 15 g/dL in gallbladder bile. 
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 Major solute components of bile by moles precent include bile acids 
(80%) lecithin and traces of others phospholipids (16%) and unesterified 
cholesterol (4.0%).  In the lithogenic state the cholestral value can be as high as 
8 to 10%.Other constituents include conjugated bilirubin, protein, electrolytes, 
mucus, and often drugs and their metabolites. 
 The total daily basal secretion of hepatic bile approximately 500 to 600 
mL. Three mechanisms are important in regulating bile flow:  
 Active transport of bile acids from hepatocytes into the bile 
canaliculi,  
 Active transport of other organic anions,  
 Cholangiocellular secretion.  
The last is a secretin-mediated and cyclic AMP –dependent mechanism 
that result in the secretion of a sodium-and bicarbonate-rich fluid into the bile 
ducts. 
 Active vectorial secretion of biliary constituents from the portal blood 
into the bile canaliculi is driven by a distinct set of polarized transport systems 
at the basolateral and the canalicular plasma membrane domains of the 
hepatocyte. Two sinusoidal bile salt uptake system have been cloned in humans 
the Na+/taurocholate cotransporter and the organic anion transporting proteins  
which also transport a large variety of non-bile salt organic anions.  
For some of these transporters genetic defects have been identified that 
are associated with various forms of cholestasis or defects of bilary excretion. 
BSEp is defective in progressive familial intraherpatic cholestasis type   
2. Mutations of MRP2 cause the Dubin johonson syndrome an inherited from of 
conjucted hyperbilirubinemia.  
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A defective MDR3 results in PFIC-3. The cystic fibrosis transmembrane 
regulator located on bile duct epithelial cells is defective in cystic fibrosis which 
is associated with impaired cholangiocellular bile formation and chronic 
cholestatic liver disease. 
THE BILE ACIDS:  
 The primary bile acids (cholic acid and chenodeoxy-cholic acid) are 
synthesized from cholesterol in the liver conjugated with glycine or taurine and 
excreted into the bile.  
Secondary bile acids including deoxycholate and lithocholate are formed 
in the colon as bacterial metabolites of the primary bile acids. However 
lithocholic acid is much less efficiently absorbed from the colon than 
deoxycholic acid. The biliary excretion of cholesterol, bile acids are necessary 
for the normal intestinal absorption of dietary fats mainly cholesterol and fat - 
soluble  vitamins. 
 Bile acids also serve as a major physiologic driving force for hepatic bile 
flow and aid in water and electrolyte transport in the small bowel and colon. 
GALLBLADDER AND SPHINCTERIC FUNCTIONS: 
 Hepatic bile is “concentrated “within the gallbladder by energy dependent 
transmucosal absorption of water and electrolytes. Allmost the entire bile acid 
pool may be sequestered in the gallbladder following an overnight fast for 
delivery into the duodenum with the first meal of the day. The normal capacity 
of the gallbladder is about 30 mL of bile.  
Composition of hepatic bile and gall bladder bile. 
Hepatic Bile (pH 7.1 to 8.5) Gall Bladder Bile 
 (pH 5.5 to 7.7) 
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Specific gravity 1.009 to 1.013 1.026 to 1.032 
Water 97.00 85.921 
Solids 2.52 14.08 
Bile acids 1.93 9.14 
Mucin & bile pigments 0.53 2.98 
Cholesterol 0.06 0.26 
Fats and fatty acids 0.14 0.32 
Inorganic salts 0.84 0.65 
pH 7.1 to 8.5 5.5 to 7.7 
 
 
Gall Bladder and the storage of Bile.   
                    The liver secretes between 500-1000 ml of Bile per day. Which 
travels down the hepatic ducts and passes along the cystic duct to be stored in 
the gall bladder. 
Gall bladder 
 It is a pear shared dilated sac, lined by mucous membrance, a thin layer of 
smooth muscle fibers and fibro elastic tissue. 
          The mucosal epithelium consists of columnar cells showing microvillus 
in folded basal membrance and numerous mitochondrial features. 
          The characteristic of cells involved in active transport. 
          The capacity of gall bladder is 50ml 
         The mucosa of the cystic duct shows spiral folds which act as a spiral 
valve (Valved of Heister). The cystic duct joints the hepatic duct to form the 
common bile duct. 
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         It joints the main pancreatic duct to open into the duodenum. 
         Bile is secreted continuously by the liver. It is required only intermittently 
by the intestine. Therefore when not required it is stored in the gall bladder.   
Regulation of Biliary Secretion  
            The bile is permitted to enter the duodenum which is determined by two 
factores. 
 The rate of formation of bile by the liver of choleresis. 
 The evalution of stored bile from the gall bladder of chole cyst kinesis.  
 
THE RATE OF SECRETION OF HEPATIC BILE [CHOLERESIS] 
 In man it is about 13to 65 ml per hour and is influenced by several        
factors. 
 Which increase the output of bile without necessarily changing its 
concentration is called cholereties.  
 Affecting the solid contents is called hydro-cholereties. 
 Bile salts act as powerful cholereties. 
 This biliary ductal component of bile secretion is under neuro 
hormonal control. 
 Hydrochloric acid and chime in the duodenum have also been 
shown to increase water and chime in the duodenum have also 
been shown. 
EVACUATION OF BLADDER BILE [CHOLECYSTOKINESIS] 
 Evacuation of bile into the duodenum is brought about by neural 
and hormonal control. 
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 Which bring about evacuation of stored bile in to the duodenum by 
contracting the gall bladder are called cholagogues or 
cholecystogogues.  
 Intrinsic and extrinsic nerves are involved in chole cyst kinesis.  
 The reflexes through either intrinsic plexuses or by extrinsic 
afferents impringing on vassal nuclei [probably vaso-vagal] to 
inhibit the gall bladder contractions [choledocho-duodenal 
sphincter] 
FUNCTIONS OF BILE 
 Bile salts are most important for their role in digestion and absorption 
particularly of fats. 
Provides the alkaline  pH  for  neutralization of  acid chime.  
EMULSIFICATION OF FATS 
 The detergent or hydrotropic property of bile helps to lower the 
interfacial tension between the oil and water phases in a mixture.  
FORMATION OF MICELLAR SOLUTIONS 
 The activated pancreatic lipase are known to be absorbed on to the 
surface of the lipid globules in the emulsion and the biolytic activity of 
pancreatic lipase.  
SECRETION OF PANCREATIC JUICE 
          Bile salts in the duodenum stimulate secretion of pancreatic juices. 
ENTEROKINASE 
 Bile salts increase the release of enterokinase from the microvillous 
membrane of the duodenal mucosal cells. 
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EXCRETION 
          Bile acts as an important vehicle for the excretion of numerous drugs, 
toxins and salts of heavy metals like copper, zinc and mercury. 
LAXATIVE 
 Mild laxative effect on the gut by stimulating peristalsis in the small 
bowel. 
ANTISEPTIC ACTION 
Inhibits  the growth of certain bacteria. 
BLOOD SUPPLY TO THE LIVER 
          Blood enters the liver through the portal vein and the hepatic artery. 
PORTAL VEIN 
 It is formed by the union of the superior mesenteric vein and splenic vein. 
The superior mesenteric vein drains from the major part of the gastrointestinal 
tract. The splenic vein is the venous drainage of the spleen, pancreas, gall 
bladder and stomach.  
Superior mesenteric vein drains mainly in to the right lobe of liver.  
Splenic vein mainly goes to left lobe. 
The portal vein divides into branches which within the portal tract from 
sinusoids between the plates of hepatic cells. 
The various sublobar veins unite to from the hepatic vein. 
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HEPATIC ARTERY 
 It supplies the arterial blood to the liver and supplies the portal tracts and 
the bile ducts. It anastomoses within the liver parenchyma in a complex manner 
draining both into the sinusoids as well as into the branches of the portal vein. 
It is the common venous outflow of the liver. 
NERVOUS INNERVATION OF LIVER  
 The nerve supply to the liver is arranged in two plexuses at the hilum of 
the organ the anterior plexus from left celiac ganglion 
 The left vagus provides the parasympathetic supply to this plexus. 
           Both the anterior and posterior plexuses join together to provide intra 
hepatic innervations. The right phernic nerve also supplies sensory fibres to the 
liver. 
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BLOOD  SUPPLY  TO LIVER 
 
 
 
FUNCTION OF LIVER  
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1. STORAGE  FUNCTION: 
 Many substances are stored in liver.They are  
 Glycogen 
 Amino acids  
 Iron 
 Folic acid 
 Vitamin A, B12 and D. 
2. SYNTHETIC FUNCTION: 
 Plasma proteins  
 Blood group substances 
 Clotting factors  
 Somatomedin 
 Heparin  are synthesized in liver. 
3. SECRETION OF BILE: 
 Liver secrets bile, it contains bile salts, bile pigments, cholesteral, fatty 
acids and lecithin. 
 The bile salts are required for digestion and absorption of  fats in the 
intestine. 
4. METABOLIC FUNCTION: 
 Carbohydrate  
 Proteins  
 Lipids 
 Vitamins and many horomones are metabolished in liver. 
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5. EXCRETORY FUNCTION: 
Liver excretes cholesterol, bile pigments, heavy metals (lead, arsenic, 
bismuth ), toxins, bacteria-typhoid, virus. 
6. METABOLIC FUNCTION: 
Heat is produced in liver due to metabolic actions. 
7. HEMOPOIETIC FUNCTION: 
In fetus (Hepatic stage) the blood cells are produced in liver. 
8. HEMOLYTIC FUNCTION: 
RBC life span is 120 days  
It is destroyed by the kupffer’s cells in liver. 
9. DEFENSIVE AND DETOXIFICATION FUNCTIONS: 
Detoxification of foreign bodies  
Bacteria are swallowed and digested by phagocytosis  
Antibody production 
Detoxification -Removal of toxic property. 
 Metabolic degradation 
 Toxic substances converted into non-toxic materials - 
conjugation with glucuronic acid or sulphates. 
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DEGRADATION OF HEME TO BILE PIGMENTS 
Eryhrocyts have a life span of 120 days.  At the end of this 
period, they are removed from the circulation.  Erythrocytes are taken 
up and degraded by the macrophages of the reticuloendothelial (RE) 
system in the spleen and liver.   
The hemoglobin is cleaved to the protein part globin and non-
protein heme.  About 6 g of hemoglobin per day is broken down and 
resynthesized in an adult man (70 kg). 
 Fate of globin:  The globin may be reutilized as such for the 
formation of hemoglobin or degraded to the individual amino acids.  
The latter undergo their own metabolism, including participation in 
fresh globin synthesis.  
 Sources of Heme:  It is estimated that about 80% of the heme 
that is subjected for degradation comes from the eythrocytes and the 
rest (20%) comes from immature RBC, myoglobin and cytochromes. 
 Heme oxygenase: A complex microsomal enzyme namely heme 
oxygenase utilizes NADPH and O2 and cleaverage methenyl bridges 
between the two pyrrole rings (A and B) to form biliverdin.  
Simultaneously, ferrous iron (Fe2+) is oxidized to ferric form (FE3+) 
and released.  The products of heme oxygenase reaction are biliverdin 
(a green pigment), Fe3+ and carbon monoxide (CO).  Heme promotes 
the activity of this enzyme. Biliverdin is excreted in birds and 
amphibian while in mammals it is further degraded. 
  
73 
 
Biliverdin reducase: Biliverdin’s methenyl bridges (between the 
pyrrole rings C and D) are reduced to methylene group to form 
bilirubin (yellow pigment).  This reaction is catalysed by an NADPH 
dependent souble enzyme, biliverdin reductase. One gram of 
hemoglobin on degradation finally yields about 35 mg bilirubin.   
Approximately 250 - 350 mg of bilirubin is daily produced in human 
adults. The term bile pigments is used to collectively represent 
bilirubin and its derivatives. 
Transport of bilirubin to liver : Bilirubin is lipophilic and therefore 
insoluble in aqueous solution.  Bilirubin is transported in the plasma 
in a bound (non-covalently) form to albumin.  
Albumin has two binding sites for bilirubin,  
 High affinity site  
 Low affinity site.   
Approximately 25 mg of bilirubin can bind tightly to albumin 
(at high affinity sites) per 100 ml of plasma. The rest of the bilirubin 
binds loosely (at the low affinity sites) which can be easily detached 
from albumin to enter the tissues.  Certain drugs and antibiotics (e.g. 
sulfonamides, salicylaes) can displace bilirubin from albumin.  Due to 
this, bilirubin can enter the central nervous system and cause damage 
to neurons. 
 As the albumin-bilirubin complex enters the liver, bilirubin 
dissociates and is taken up by sinusoidal surface of the hepatocytes by 
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a carrier mediated active transport.  The transport system has a very 
high capacity and therefore is not a limitation for further metabolism 
of bilirubin.  Inside the hepatocytes, bilirubin binds to a specific 
intracellular protein namely ligandin. 
Conjugation of bilirubin 
 In the liver, bilirubin is conjugated with two molecules of 
glucuronate supplied by UDP- glucuronate.  This reaction, catalysed 
by bilirubin glucuronyltransferase (of smooth endoplasmic 
reticulum) results in the formation of a water soluble bilirubin 
diglucuronide.When bilirubin is in excess, bilirubin  
monoglocuronides also accumulate in the body. The enzyme bilirubin 
glucuronyltransferase can be induced by a number of drugs. (e.g. 
Phenobarbital) 
Excretion of bilirubin into bile 
 Conjugated bilirubin is excreted into the bile canaliculi against a 
concentration gradient which then enters the bile.  The transport of 
bilirubin diglucuronide is an active, energy-dependent and rate 
limiting process.  This step is easily susceptible to any impairment in 
liver function.  Normally, there is a good coordination between the 
bilirubin conjugation and its excretion into bile.  Thus almost all the 
bilirubin (>98%) that enters bile is in the conjugated form.   
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Fate of bilirubin 
 Bilirubin glucuronides are hyrolysed in the intestine by specific 
bacterial enzymes namely B-glucuronidases to liberate bilirubin.  
The latter is then converted to unrobilinogen (colourless compound),  
a small part of which may be reabsorbed into the circulation. 
Urobilinogen can be converted to urobilin (an yellow colour 
compound) in the kidney and excreted.  The characteristic colour of 
urine is due to urobilin. 
 A major part of urobilinogen is converted by bactereia to 
stercobilin which excreted along with feces.  The characteristic 
brown colour of feces is due to stercobilin. 
 
BILIRUBIN METABOLISM 
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BILIRUBIN METABOLISM 
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JAUNDICE 
 The term jaundice originated from the French “Jaune” which means 
“Yellow”. 
 Jaundice refers to the yellow appearance of the sclera, and mucous 
membranes, skin owing to an excess of serum bilirubin concentration in the 
body fluids.  Normal bilirubin level 0.8 to 1.2mg / dl. 
 Clinically apparent Jaundice in children and adult occur when the serum 
concentration of bilirubin reaches 2-3mg /dl . 
Internal tissues and body fluids are colored  yellow but not the  brain as 
bilirubin  does not  cross the blood brain barrier other than in the immediate 
neonatal period. 
Prevalence of Jaundice: 
 The survey collected information on the prevalence of Jaundice, malaria 
asthma among all household members. 
 The survey found that 2.4% suffered from Jaundice during the 12 months 
preceding the survey in India (2011-2012) 
 Prevalence of Jaundice is equally prevalent in urban and rural areas.  
Male child are more likely than female child to suffer from Jaundice. 
 Although cases occurred throughout the year, more than 59% occurred 
during June-September, which are the summer and monsoon months. 
 Finally the study found the annual incidence of Laboratory supported 
case of viral Hepatitis to be 1.24 per 1000 population, which suggested that it is 
a major public health problem in India. 
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Mechanisms producing Jaundice:  
 Haemolysis 
 Impaired hepatic bilirubin transport 
 Hepatocellular damage 
 Cholestasis (impaired bile flow) 
Types: 
 Haemolysis Jaundice 
 Hepatocellular Jaundice 
 Obstructive Jaundice 
HAEMOLYTIC JAUNDICE 
This results from  increased destruction of red blood cells or their 
precursors in the narrow causing increased  builirubin production.  
 Jaundice due to haemolysis is usually mild because a healthy liver can 
excrete a bilirubin load 6 times greater than normal before unconjugated 
bilirubin mechanism is immature and in patients with liver disease  
CILINICAL FEATURES : 
 Increased excretion of  bilirubin 
 Stercobilinogen leads to normal colored stools [or] dark stools. 
 Increased urobilinogen excretion casused the urine to turn dark on 
standing as urobilin is formed. 
 Pallor due to anemia 
 Splenomegaly –due to excessive reticulo endothelial activity. 
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INVESTIGATION: 
 The Plasma bilirubin is less than 100µ mol [6mg/d1] 
 Liver Function test-Normal 
 No brilirubinuria 
 Unconjugated Hyper bilirubinemia  present  
 Haemolytic aaemia present. 
 
MANAGEMENT  
Splenectomy results in 
 Persistant anemia  
 Sever hemolytic or aplastic anemia. 
 History of family members death from this disease. 
 Evidence of cholecystitis , cholelithiasis. 
 
HEPATO CELLULAR JAUNDICE: 
 Hepato cellular Jaundice results from inability of the liver to transport 
bilirubin into bile as a result of liver cell damage.Bilirubin transport across the 
hepatocytes may be impaired. Between uptake of bilirubin [unconjugated] and 
transport of conjugated bilirubin   in to the canaliculi. 
 Swelling of liver cells and oedema result from the disease may cause 
obstruction of the billiary canaliculi concentration in the blood of unconjugated 
and conjugated bilirubin is increases.  Bilirubin transport in disturbed. 
CHOLESTATIC JAUNDICE:  
It is a failure of bile flow between the hepatocyte and the duodenum. 
Jaundice becomes progressively severe in unrelieved cholestasis because 
conjugated bilirubin is unable to enter the bile canaliculi and passes back  into 
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the blood. Failure of clearance of unconjugated bilirubin arriving at the  liver 
cells. 
AETIOLOGY:  
 Failure of the hepatocytes to generate bile flow.  
 Obstruction to bile flow in the bile ducts in the portal tracts.  
 Obstruction to bile flow in the extra hepatic bile ducts between the 
porta hepatic and the papillae of Vater 
Clinical Features 
Early Features 
 Dark urine 
 Pale stools 
 Pruritus 
Late features 
 Xanthalasma and xanthomas 
 Mal absorption 
 Weight loss 
 Steatorrhoea 
 Bleeding tendency 
 Fever 
 Rigors 
 Pain 
 Biliary infection  
 Hepatic abscess 
 Ultra sonography – do not show dilated bile duct.  
 Anti-mitochondrial antibody.  
 ERCP is the best investigation if the biliary tract is dilated.  
 Dilatation extends to the lower common bile duct.  
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Management 
 This depends on the underlying cause of the Cholestasis. 
PATHOPHYSIOLOGY OF JAUNDICE 
Both unconjugated bilirubin and bilirubin glucuronides accumulate 
systemically and deposit in tissues, giving rise to the yellow discoloration of 
jaundice. This is particularly evident in the yellowing of the sclerae (icterus). 
There are two important pathophysiologic differences between the two forms of 
bilirubin. 
 Unconjugated bilirubin is virtually insoluble in water at physiologic pH 
and is tightly complexed to serum albumin. This form cannot be excreted in the 
urine even when blood levels are high.  
Normally, a very small amount of unconiugated bilirubin is present as an 
albumin-free anion. This fraction of unbound bilirubin may diffuse into tisues, 
particularly the brain in infants, and produce toxic injury. The unbound plasma 
fraction may increase in severe hemolytic disease or when protein-binding 
drugs displace bilirubin from albumin. Hence, hemolytic disease of the newborn 
(erythroblastosis fetalis) may Lead to accumulation of unconjugated bilirubin in 
the brain, which can cause severe neurologic damage, referred to as kernicterus.  
Conjugated bilirubin is water soluble, nontoxic, and only loosely bound 
to albumin. Because of its solubility and weak association with albumin, excess 
conjugated bilirubin in plasma can be excreted in urine. With prolonged 
conjugated hyper bilirubinemia, a portion of circulating pigment may become 
bilirubin bound to albumin (the delta-fraction). 
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 In the normal adult, serum bilirubin levels vary between 0.3 and 1.2 
mg/dl., and the rate of systemic bilirubin production  is equal to the rates of 
hepatic uptake, conjugation, and biliary excretion.  
Jaundice becomes evident when the serum bilirubin levels rise above 2.0 
to 2.5 mg/dL; levels as high as 30 to 40 mg/dL can occur with severe disease. 
Jaundice occurs when the equilibrium between bilirubin production and 
clearance is  disturbed by one or more of the following mechanisms, 
 (1) Excessive production of bilirubin,  
(2) Reduced hepatocyte uptake,  
(3) Impaired conjugation,  
(4) Decreased hepato cellular excretion,  
(5) Impaired bile flow (both intrahepatic and extrahepatic).  
The first three mechanisms produce unconjugated hyperbilirubinemia, 
and the latter two produce pre-dominantly conjugated hyperbilirubinemia.  
More than one mechanism may operate to produce jaundice, especially 
hepatitis, which can produce unconjugated and conjugated hyperbilirubinemia.  
CAUSE OF JAUNDICE IN INFANTS AND OLDER CHILDREN: 
1. Viral Hepatitis: -  Hepatitis A,B,C,D,E,G, Epstein –Barr virus,  
                        Cytomegalovirus. 
2. Autoimmune hepatitis 
3. Metabolic disorders 
4. Herediatary Hyberbilirubinemias 
 Gilbert’s syndrome, Dubin – Johnson Syndrome, Rotor 
Syndrome, Crigler – Najjar Syndrome 
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 Alpha – antitrypsin deficiency 
 Cystic Fibrosis 
 Hemochromatosis 
 Wilsons’ disease. 
5. Biliary tract disease 
 Cholecystitis, cholelithiasis, caroli’s disease, choledochal cyst. 
6. Tumour 
Hepatic, biliary, Pancreatic, Peritoneal, Duodenal 
7. Red blood cell abnormalities 
Sickle cell disease  
Thalassemia 
Hemolyis 
8. Impaired delivery of bilirubin to liver 
Congestive heart failure  
Cirrhosis 
9. Drugs / Toxins 
Acetaminophen 
Valproate  
Chlorpromazine 
Amanita toxin 
10. Others 
 Sepsis 
SIGN AND SYMPTOMS 
 Loss of appetite 
 Nausea 
 Vomiting 
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 Fever, chills 
 Yellow discolouration of eyes and tongue 
 Yellow discolouration of skin 
 Severe constipation 
 Lethargy  
 weight loss 
 Pruritus 
 Arthralgia 
 Abdominal pain 
 Common in Right-Upper abdominal pain 
 Urine colour change: 
Dark yellow colour (or) orange urine 
 Stools 
Acholic stool 
 Liver and spleen:  
Enlarged and tenderness of the liver 
Enlarged and tenderness of the spleen 
VIRAL HEPATITIS A (INFECTIVE HEPATITIS) 
Viral hepatitis A (HAV) accounts for about 150,000 of the 500,000-
600,000 new cases of viral hepatitis that occur each year in the United States. 
The hepatitis caused by HA V is an acute illness (acute viral hepatitis) that 
never becomes chronic. 
 At one time, hepatitis A was referred to as "infectious hepatitis" because 
it could be spread from person to person like other viral infections. Infection 
with hepatitis A virus can be spread through the ingestion of food or water, 
especially where unsanitary conditions allow water or food to become 
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contaminated by human waste containing hepatitis A (the faeco-oral mode of 
transmission). 
 Hepatitis A typically is spread among household members and close 
contacts through the passage of oral secretions (intimate kissing) or stool (poor 
hand washing). It also is common to have infection spread to customers in 
restaurants and among children and workers in day care centers if hand washing 
and sanitary precautions are not observed. 
 Hepatitis A - Caused by the hepatitis A virus, Hepatitis A is often 
spreads because of poor personal hygiene habits, such as not washing and after 
a bowel movement. You can also get hepatitis A by eating foods or drinking 
beverages contaminated with the virus. Hepatitis A is a common form of viral 
hepatitis in the United States. This disease is responsible for serious health 
problems. 
Hepatitis A Virus  
 
Group of -  Entero  Viruses 
          - HAV is Highly Infectious 
Size  - 27 nm 
 - Spread by the faecal -Oral route 
Nucleic Acid -  It is a RNA Virus 
 
Incubation Period - 2-4 Weeks.  
 
 Children are Commonly affected  
 
           HAV is spread by ingestion of  contaminated water and foods and 
is shed in the stool for  2 to 3 weeks before and 1 week after the onset of 
jaundice. HAV is not shed in any significant quentities in saliva, urine, or 
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semen.   HAV does not causes chronic hepatitis or a carrier state and only rarely 
causes fulminate hepatitis  
SIGNS AND SYMPTOMS:  
 Loss of appetite  
 Nausea  
 Vomiting  
  Fever  
  Weakness  
 Tiredness  
 Abdomeninal pain 
Less Common symptoms include:  
 Dark urine  
 Light -coloured stools  
 Fever 
 
Acute parenchymal liver disease due to virual hepatitis, 
 Prolonged alcohol abuse  
 Chronic hepatitis 
 Cirrhosis.  
 
Serologic Diagnosis. 
Specific antibody against HAV of the immunoglobulin (Ig) M type 
appears in blood at the onset of symptoms, constituting a reliable marker of 
acute infection.  
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Fecal  shedding of  the virus ends as the IgM titer rises. The IgM response 
usually  begins to decline in a few months and is followed by the appearance of 
IgG anti-HAV. The latter persists for years  perhaps for life, providing pro- 
tective immunity against reinfection by all strains of HAV. Hence, the HAV 
vaccine is effective.  
 
 
 
HEPATITIS “B” VIRUS :  
 
Nucleic Acid  -  DNA Virus  
Size   - 42nm 
Incubation period - 4-20 weeks. 
Liver disease due to HBV is an enormous problem globally, with an 
estimated worldwide carrier rate of 350 million. 
HBV has a prolonged incubation period (4 to 26 weeks).   Unlike  HAV, 
HBV remains in the blood up to and during active episodes of acute and chronic 
hepatitis. It is also present in all physiologic and pathologic body fluids, with 
the exception of stool.  
 HBV is a hardy virus and can withstand extremes of temperature and 
humidity. Thus, whereas blood and body fluids are the primary vehicles of 
transmission, virus may also be spread by contact with body secretions such as 
semen, saliva, sweat, tears, breast milk, and pathologic effusions. 
Spread from an infected mother to a neonate during birth (vertical 
transmission) is common. These neonatal infections often lead to the carrier 
state for life. 
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Hepatitis B virus (HBV) can produce, 
 (1) Acute hepatitis   
(2) Chronic hepatitis, which may evove to cirrhosis,  
(3) Fulminant hepatitis with massive liver necrosis,  
 (4) The backdrop for hepatitis D virus infection.  
Patients with chronic hepatitis represent carriers of actively replicating 
virus and hence are a source of infection to other individuals. HBV also plays 
an important role in the development of hepato cellular carcinoma. 
Patients with Immune defects suffer relatively mild liver injury (but are 
more prone to develop a carrier state). HBV evokes both a humoral and cellular 
immune response. 
 HBsAg appears before the onset of symptoms, peaks during overt 
disease, and then declines to undetectable levels in 3 to 6 months.  
 HBeAg, HBV-DNA, and DNA polymerase appear in the serum soon 
after HBsAg, and all signify active viral  replication.  
 IgM anti-HBc becomes detectable in serum shortly  before the onset of 
symptoms, concurrent with the onset of  elevation of serum 
aminotransferases. Over months, the  IgM antibody is replaced by IgG 
anti-HBc. 
  Anti-HBe is detectable shortly after the disappearance of HBeAg, 
implying that the acute infection has peaked. 
  IgG anti-HBs does not rise until the acute disease is over and is usually 
not detectable for a few weeks to several months after the disappearance 
of HBsAg. Anti-HBs may persist for life, conferring protection; this is 
the basis for current vaccination strategies using noninfectious HBsAg. 
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The carrier state is defined by the presence of HBsAg in of complete 
virions, and patients may be asymptomatic and without liver damage. In serum 
for 6 months or longer after initial detection. The presence of HBsAg alone does 
not necessarily indicate replication contrast, chronic replication of HBV virions 
is characterized by persistence of circulating HBsAg, HBeAg, and HBV DNA, 
usually with anti-HBc and occasionally with anti-HBs. In these patients, 
progressive liver damage may occur. 
The major routes of transmission are inoculations and  blood transfusions. 
Intravenous drug use accounts for 60% of  cases Sexual transmission is the only 
presumed risk factor  in 15% of cases, although the case risk for transmission is 
low 12 events per 1000 person-years in the sexual  HCV-infected patients)." he 
risk of perinatal transmission  is much lower with hepatitis C (6% of births  to 
infected mothers) than with hepatitis B 
Serologic Diagnosis 
The incubation period for HCV hepatitis ranges from 2 to 26 weeks, with 
a mean between 6  leeks. HCV RNA is detectable in blood for 1 to 3weeks, 
coincident with elevations in serum transaminases  . 
 In symptomatic acute HAV infection, anti-HAV antibodies are detected 
in only 50% to 70% of patients; in the remaining patients, the anti-HAV 
antibodies emerge after 3 to 6 weeks. The clinical course of acute HAV 
hepatitis  is milder than that of HBV;  
In chronic HAV infection, circulating HAV RNA persists in many 
patients despite the presence of neutralizing antibodies, including more than 
90% of patients with chronic disease  . Hence, in patients with symptoms of 
chronic hepatitis, HAV RNA testing must be performed to assess viral 
replication  and  to confirm the diagnosis of HCV infection. A clinical feature 
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that is quite characteristic of chronic HCV infection is episodic elevations in 
serum aminotransferases, with intervening normal or near-normal periods. 
Prevention 
 Hepatitis B Vaccine containing HBsAg (Engerix) (Active immunization) 
 Intramusclar injection of Hyperimmune serum globulin prepared from 
blood containing anti-HBs should be given within 24 hours or at most a 
week. 
 Hyper immune globulin-active-passive immunization. 
HEPATITIS "C "VIRUS   
Group    - Flavivirus  
Nucleic acid   - RNA virus  
Size    - 30 - 38nm  
Incubation period  - 2 -26 weeks  
Mode of transmission  - Blood products 
 
 Parenteral drug abusers  
 Sporadic infection  
 Sexual and vertical transmission  
CHRONIC INFECTION  -  Chronic liver disease 
PREVENTION   - No vaccination 
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Serologic Diagnosis 
The incubation period for HCV hepatitis ranges from 2 to 26 weeks, with 
a mean between 6 weeks. HCV RNA is detectable in blood for 1 to 3weeks, 
coincident with elevations in serum transaminases. In symptomatic acute HCV 
infection, anti-HBV antibodies are detected in only 50% to 70% of patients;  In 
the remaining patients, the anti-HCV antibodies emerge after 3 to 6 weeks. The 
clinical course of acute HCV hepatitis is milder than that of HBV; rare cases 
may be severe and indistinguishable from HCV or HBV hepatitis.  
A clinical feature that is quite characteristic of chronic HCV infection is 
episodic elevations in serum aminotransferases, with intervening normal or 
near-normal periods. 
Hepatitis D Virus  
 Called as "hepatitis delta virus," hepatitis D virus (HDV) is a unique 
RNA virus that is replication defective, causing infection only when it is 
encapsulated by HBsAg.  
HEPATITIS D VIRUS 
Group   - Defective virus  
Incomplete virus 
Size    - 35nm 
Incubation   - 6-9 wks 
Acute coinfection occurs following exposure to serum containing both 
HDV and HBV. The HBV must become established first to provide the HBsAg 
necessary for development of complete HDV virions.  
 Super infection of a chronic carrier of HBV with a new  inoculum of 
HDV (and HBV) results in disease about 30 to 50 days later. The carrier 
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may have been previously "healthy" or may have underlying chronic 
hepatitis.  
 
Simultaneous coinfection with HBV and HDV results in hepatitis ranging 
from mild to fulminant, fulminant disease being more likely (about 3% to 4%) 
than with HBV alone. 
 When HDV is superimposed on chronic HBV infection, there are three 
possible outcomes:  
(l) Acute, severe hepatitis may erupt in a previously healthy HBV carrier;  
(2) Mild HBV hepatitis may be converted into fulminant disease;  
 (3) Chronic, progressive disease may develop (in 80% of patients), often 
culminating in cirrhosis. 
Serologic Diagnosis 
HDV RNA is detectable in the blood and in the early days of acute 
symptomatic disease. IgM anti-HDV is the most reliable indicator of recent 
HDV exposure, although its appearance is late and frequently short-lived. 
 
  Acute coinfection by HDV and HBV is best indicated by detection of 
IgM against both HDAg and HBcAg (denoting new infection with hepatitis B). 
With chronic delta hepatitis arising from HDV super infection, HBsAg is 
present in serum, and IgM anti-HDV persists for months or longer. 
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HEPATITIS E VIRUS 
Size    - 27nm  
Incubation   - 3-8 wks 
Mode of transmission - By faecal-oral route 
    - Water borne hepatitis  
Prevention   - No vaccine. 
 
Hepatitis E Virus  
Hepatitis E virus (HEV) hepatitis is an enterically transmitted, water-
borne infection that occurs primarily in young to middle-aged adults; sporadic 
infection and overt illness in children are rare. 
HEV accounts for over 50% of cases of sporadic  acute hepatitis in India, 
exceeding the frequency HAV. A characteristic feature of HEV infection is the 
high rate among pregnant women, approaching 20%. In is, the disease is self-
limiting; HEV is not associated with chronic liver disease or persist viremia. 
The average incubation period following  exposure 6 weeks. 
Serologic Diagnosis 
 Before the onset of clinical illness HEV RNA and HEV virions can be 
detected in stool and liver. The onset of rising serum aminotransferases, clinical 
illness, and elevated IgM anti-HEV titers are virtually simultaneous. Symptoms 
resolve in 2 to 40 weeks, during which time the IgM is replaced with a 
persistent IgC anti-HEV titer.  
HEPATITIS F VIRUS 
It is a virus being identified as a member of the Non A and Non B  group.  
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Recently postoperative Jaundice is getting increasing importance.  
The exact cause of postoperative cholestatic jaundice is uncertain,  
however, it may result from;  
i. Increased pigment load especially from blood transfusion from 
reabsorption of extra vascular spaces.  
ii. Decreased liver function due to hypoxemia and  hypotension. 
iii. Decreased renal bilirubin excretion due to varying degree of tubular 
necrosis.  
iv. Hepato cellular damage and decreased liver cell function may occur 
due to concurrent use of hepato toxic drugs (or) anesthetics such as 
halothane.  
HEPATITIS G VIRUS (HGV) 
Hapatitis G virus (HGV) also called hepatitis virus GB - C is a  positive 
stranded RNA agent. It presents a genomic organization common  to that of the 
Flaviviridae family and conserved sequences but has <25% homology with  
hepatitis C virus (HCV).   
Mode of spread:  
 The main infection route is parentral exposure to blood through 
transmission, hemodialysis and sharing of equipment in infecting drug 
use.  
 30% of transfusion recipients up to 80% of injecting drugs uses are 
HGV marker positive.  
  
95 
 
 Sexual transmission is suspected.  
 HGV and HIV type 1 share the same infection routes, and a significant 
proportion of HIV-1 infected subjects are HGV co-infected.  
Serum HGV RNA indicates viremia, whereas the HGV envelope  E2 
glycoprotein - specific antibody is associated with recovery. HGV RNA and E2 
Ab are almost mutually exclusive and can be found  respectively in <2% and 
9% of healthy blood donors.  
Prevalence increases in association with HEV or HBV infection.  Mother 
to child infection occurs but little is known about transmission in HIV-I-
infected mothers.  
HGV transmission rate in HIV -1 infected mothers is higher than that in 
normally immune - competent woman. 
 
OTHER VIRUSES:  
 Cytomegalovirus  
 Epstein - Barr Virus - cause abnormal liver function  
 Herpes simplex  
 Yellow fever virus. 
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CLINICAL FEATURES:  
 Jaundice by a fewdays to 2wks  
 Chills, headache, malaise  
 Anorexia  
 Nausea  
 Vomitting  
 Diarrhoea  
  Abdominal pain  
 Enlarged liver  
  Enlarged cervical lymph nodes 
 Splenomegaly in children  
  Arthralgia 
 Splenomegaly in children  
 Serum Sickness syndrome  
 Urticaria , Polyarthritis in Hepatitis B infection 
 Dark yellow urine  
 Yellow discoloration of the sclerae  
INVESTIGATIONS:  
 A plasma Aminotransferase 400 U / L  
 Plasma bilirubin  
 Alkaline phosphatase 250 U / L  
 Prothrombin time for liver damage  
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COMPLICATIONS : 
 Fulminant hepatic failure 
 Chronic hepatitis 
 Cirrhosis [Hepatitis B,C,D Virus] 
 Hepatic Encephalopathy 
 Biliary cirrhosis 
 Pancreatitis 
 Coagulopathy 
 Renal and liver failure 
 Hepatocellular carcinoma 
DIFFERENTIAL DIAGNOSIS: 
 Kalar – Azar 
 Liver abcess 
 Carotenemia 
 Cholangitis 
 
MANAGEMENT: 
Home care for a child with Jaundice 
 Bed Rest -should be continued until symptoms and signs have 
disappeared. 
 Sugar cane juice 
 Drink plenty of fluids 
 Take prescribed medicine as directed 
 Take an oral antihistamine for itching  
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MATERIALS AND METHODS 
 The study on clinical evaluation of the disease MANJAL KAMALAI 
with the trial drug  “KARISALANKANNI CHURNAM” was carried out in 
post graduate Kuzhandhai Maruthuvam Departments of Government Siddha 
Medical College, Palayamkottai.   
          50 patients of both male and female children were selected for the 
studiers and admitted in Post Graduate Kuzhandhai Maruthuvam ,In Patients 
ward for 7 days and advised for further follow up as out patients.  
 Another 30 patients were also treated with trial drug in the out patients 
ward. 
 
SELECTION OF PATIENTS: 
 The present study covers both male and female children of pediatric age 
groups. 
 All cases were carefully and thoroughly examined before admission. 
 These who fulfilled the criteria of MANJAL KAMALAI according to the 
clinical features in Siddha and modern reviews were selected with the aid of 
questionnaire. 
 The opinion of professor and lecturer was obtained and detailed history 
was recorded in the proforma of case sheet. 
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INCLUSION CRITERIA 
 Age : 1 to 12 yrs. 
 Sex : Both male and female children. 
 Yellow  discolouration of skin, sclera and mucous membrane 
 Vomiting 
 Constipation 
 Weight loss 
 Poor appetite 
 Fever 
 Abdominal pain 
 Lethargy with body ache 
 Generalised Pruritis 
 Passage of high coloured urine 
 Passage of Pale or clay coloured stools[above 1.2 mg/dl] 
 Elevated bilirubin level (2-3 mg/dl) 
 Increased levels of transaminases (ALT, AST) 
EXCLUSIONG CRITERIA: 
 Neonatal jaundice 
 Cirrhosis of liver 
 Alpha – 1 – antitrypsin deficiency  
 Galactosemia 
 Cholestasis 
 Extra hepatic biliary atresia  
 Hepatic failure. 
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STUDY OF CLINICAL DIAGNOSIS: 
 A case sheet was prepared on the basis of Siddha and Modern 
methodology to diagnose the disease and individual case sheet is maintained for 
each patient. 
 
SIDDHA DIAGNOSIC TOOLS 
Poriyal Arithal 
Pulanal Arithal 
Vinaathal 
Envagai Thervugal 
Mukkutram 
Ezhu udal kattugal 
Thinaigal 
Paruva kallangal 
Neerkuri 
Neikuri 
Mummalam (Malam, Moothiram, Viyarvai) 
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LABORATORY INVESTIGATIONS 
Blood      Urine 
Serum bilirubin     Bile salt 
 Total       Bile pigment  
 Direct      Indirect 
 
Blood   Urine    Motion 
TC   Albumin   Ova 
DC   Sugar    cyst 
ESR   Deposit   Occult Blood 
Hb%    
Specific Investigation: 
o Serum transaminases (ALT, AST) 
o Serum Alkaline Phosphate (ALT ) 
o Australian Antigen (HBs Ag) 
o Prothrombin time   
o Liver biopsy 
Scan 
 Ultra sonography of the abdomen 
 CT scan of the abdomen 
 ERCP (Endoscopic retrograde cholangio pancreatography) 
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ADMINISTRATION OF TRIAL MEDICINE: 
 The trial drug was prepared carefully according to the Siddha literature 
and given to all to patients twice a day and the dose is adjusted according to 
their age. 
 The pharmacological analysis of trial drug for its Hepatoprotective, Anti- 
inflammatory, Anti- pyretic activity was carried out in the Pharmacological 
laboratory. 
 The Biochemical analysis was performed in Biochemical laboratory. 
 Analysis of observation made from patients with signs and symptoms of 
the disease and their prognosis were recorded.  In addition to medicine the 
patients were advised diet and to attend the out-patients ward for follow up. 
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OBSERVATION AND RESULTS  
Results were observed  with respect of the following criteria 
1. Sex distribution 
2. Age distribution 
3. Religion distribution 
4. Kaalam 
5. Paruva Kaalam 
6. Thinai 
7. Socio Economic Status 
8. Clinical features 
9. Derangement of Uyirthathukkal 
10.Udal Kattugal 
11.Envagai Thervugal  
12.Neerkuri, Neikuri reference 
13.Results after treatment  
 
 
 
 
 
 
 
 
 
 
  
 
S.No Sex
1 Male children
2 Female children
 
 
 
 
 
 
 
 
 
0%
10%
20%
30%
40%
50%
60%
70%
Male children
Percentage 40%
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TABLE -1 
SEX REFERENCE 
 
 No.of.cases Percentage
 20 
 30 
Female children
60%
40%
60%
SEX REFERENCE
 
40% 
60% 
 
Male children
Female children
  
 
GRAPH SHOWING 
S.No Age Paruvam 
1 0-1 
months  
Kaapu and Sengeerai
2 1 month- 
1 Year   
Sengeerai 
3 1-3 years Thalattu, Mutham,
Varugai, Sappani
4 3-6 years Ambuli, 
chitri,Sirupillai,Sirudhu
er,Oonjal,Pillai 
5 6 years-
12 years  
Pethai,Pethumbai,mang
ai,Siruparuvam
 
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
0-1 
months 
1 month
Male 0%
Female 0%
0% 0%
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TABLE-2 
PARUVA KALAM
 No of case 
Male Female 
 - - 
 - - 
 
 
3 6 
 
5 3 
 
12 21 
-1 
Year  
1-3 years 3-6 years 6 years-12 
years 
0% 6% 10% 24%
12% 6% 42%
0%
6%
10%
24%
12%
6%
42%
PARUVAKALAM
 
Percentage  
Male Female 
- - 
- - 
6% 12% 
10% 6% 
24% 42% 
 
Male
Female
  
 
SOCIO-ECONOMIC STATUS OF THE PATIENTS
S.No Socio -
1 
2 Middle class
3 
 
 
 
 
 
 
 
 
 
75%
80%
85%
90%
95%
100%
Rich
Middle Class
Poor
SOCIO
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TABLE-3 
Economic status No. of cases 
Poor 43 
 5 
Rich 2 
4%
10%
86%
86%
10%
4%
-ECONOMIC STATUS 
 
Percentage 
86% 
10% 
4% 
 
Rich
Middle Class
Poor
  
 
 
S.no Food habits
1 Vegetarian  
2 Non-vegetarian
 
 
 
 
 
 
 
 
 
109 
TABLE-4 
DIET REFERENCE 
 No. of cases 
7 
 43 
14%
86%
Food habits
Vegetarian Non-vegetarian
Percentage 
14% 
86% 
 
  
 
 
 
S.no Thinai
1 Kurinji
2 Mullai
3 Marutham
4 Neithal
5 Paalai
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TABLE-5 
THINAI 
 No.of cases Percentage
 1 
 - 
 46 
 3 
 - 
2%
92%
6% 0%
THINAI
 
2% 
- 
92% 
6% 
- 
 
Kurinji
Marutham
Neithal
Mullai
Paalai
  
 
S.no Paruva kaalam
1 Kaar kaalam[Sept-
2 Koothir kaalam [Nov
karthigai] 
3 Munpani [Jan-feb,
4 Pinpani [March-april
5 Elavenil [May-june
6 Mudhuvenil [July-
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20%
40%
60%
80%
100%
Mudhuvenil
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Munpani
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Elavenil 
Kaar kaalam
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TABLE-6 
PARUVA KAALAM 
 No. of cases
oct, Avani-puratasi] 15 
-dec, Iyppasi- 23 
 Margazhi-thai] 1 
 ,Masi-panguni] 2 
, Chithirai-vaigasi] - 
august, Aani-aadi] 9 
Paruva kaalam
18%
4%
2%
46%
0%
30%
30%
0%
46%
2%4
18%
PARUVA KAALAM
 Percentage 
 
30% 
46% 
2% 
4% 
- 
18% 
 
Mudhuvenil
Pinpani
Munpani
Koothir kaalam
Elavenil 
Kaar kaalam
  
 
THIRIDHOSA REFERENCE
Taste showing the derangement of vatham
S.no Classification of vatham
1 Pranan 
2 Abanan 
3 Viyanan 
4 Uthanan 
5 Samanan 
6 Nagan 
7 Koorman 
8 Kirukaran 
9 Devathathan 
10 Thananjeyan 
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112 
TABLE-7 
 
 
 No. of cases Percentage
50 
50 
50 
43 
50 
50 
- 
50 
50 
- 
 
 
Utha
nan
Sam
anan
Nag
an
Koor
man
Kiru
kara
n
Deva
that
han
Than
anje
yan
86% 100% 100% 0% 100% 100% 0%
86%
100% 100%
0%
100% 100%
0%
  
100 
100% 
100% 
86% 
100% 
100% 
- 
100% 
100% 
- 
 
Pranan
Abanan
Viyanan
Uthanan
Samanan
Nagan
Koorman
Kirukaran
Devathathan
Thananjeyan
  
 
SHOWING THE DERANGEMENT OF PITHAM
S.no Classification of pitham
1 Anila pitham 
2 Ranjakam 
3 Sathakam 
4 Prasagam 
5 Aalosakam 
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TABLE-8 
 No. of cases Percentage
50 
50 
50 
50 
- 
m
Sathaka
m
Prasaga
m
Aalosaka
m
100% 100% 100% 0%
100% 100% 100%
0%
PITHAM
 
 
100% 
100% 
100% 
100% 
- 
 
Anila pitham
Ranjakam
Sathakam
Prasagam
Aalosakam
  
 
SHOWING THE DERANGEMENT OF KAPHAM
S.no Classification of kabam
1 Avalambagam 
2 Kilethagam 
3 Pothagam  
4 Tharpagam  
5 Santhigam  
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TABLE-9 
 No. of cases
 
  - 
50 
50 
12 
- 
am
Pothaga
m 
Tharpag
am 
Santhiga
m 
100% 24% 0%
100% 100%
24%
0%
KAPHAM
 
 Percentage 
 
- 
100% 
100% 
24% 
- 
 
Avalambagam 
Kilethagam
Pothagam 
Tharpagam 
Santhigam 
  
 
 
EAZHUUDARKATTUGAL REFERENCES
S.no Udarkattugal
1 Saaram
2 Senneer
3 Oon 
4 Kozhuppu
5 Enbu 
6 Moolai
7 Sukkilam
8 Suronitham
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Senn
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100% 100%
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TABLE-10 
  
No.of cases percentage
 50 100%
 50 100%
- 
 - 
- 
 - 
 - 
 - 
 
Oon Kozh
uppu
Enbu Mool
ai
Sukkil
am
Suron
itham
0 0 0 0 0 0
0 0 0 0 0 0
Udarkattugal
 
 
 
 
 
- 
- 
- 
- 
- 
- 
 
percentage
  
 
ENNVAGAI THERVUGAL REFERENCES
S.no Ennvagai 
thervugal
1 Naa 
2 Niram 
3 Mozhi 
4 Vizhi 
5 Sparisam
6 Malam 
7 Moothiram
8 Naadi 
Pitha kabam
Kaba pitham
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Percentage 100%100% 0%
100%100%
0%
ENNVAGAI THERVUGAL REFERENCES
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TABLE-11 
 
 
No.of cases Percentage
50 100%
50 100%
- 
50 100%
 45 
50 100%
 50 100%
 
 
18 
Viz
hi
Spa
risa
m
Mal
am
Mo
oth
ira
m
Na
adi 
Pit
ha 
kab
am 
Kab
a …
100% 90% 100%100% 26%
100%
90%
100%100%
26%
Naa
Niram
Mozhi
Vizhi
Sparisam
Malam
Moothiram
Naadi Pitha kabam Kaba pitham
 
 
 
 
 
- 
 
90% 
 
 
26% 
 
  
 
 
S.No Neikuri
1. Aravupol
2. Aazhipol
3. Muthupol
 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Aravupol
Percentage 0%
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Table - 12 
NEIKURI 
 No.of Cases Percentage
 - - 
 50 100% 
 - - 
 
 
 
 
 
 
 
 
 
Aazhipol Muthupol
100% 0%
100%
0%
NEIKURI
 
 
Percentage
  
 
S.No Neerkuri 
1. Niram 
2. Edai 
3. Manam 
4. Nurai 
5. Enjal 
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Table - 13 
NEERKURI 
Changes No of Cases Percentage
Dark yellow 
Colour Urine 
 
50 100 %
- - - 
- - - 
Nurai was 
observed in 
34 cases 
34 68%
- - - 
 
 
 
 
 
 
 
Edai Manam Nurai Enjal
0% 0% 68% 0%
0% 0%
68%
0%
NEERKURI
 
 
 
 
Niram
Edai
Manam
Nurai
Enjal
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Table -14 
RELIGION DISTRIBUTION 
S. No Religion No of cases Percentage 
1. Hindu 31 62 % 
2. Christian 9 18 % 
3. Muslim 10 20 % 
 
 
 
  
62%
18%
20%
RELIGION 
Hindu
Christian
Muslim
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TABLE -15 
CLINICAL FEATURES DURING ADMISSION 
S.NO Clinical Features  During 
Admision 
During 
discharege   
No of cases 
No. of cases  
1 Loss of appetite 50 Nil 
2 Nausea  50 Nil 
3 Vomiting 43 Nil 
4 Fever 45 Nil 
5 Yellow Coloured 
Conjunctiva, sclera and 
tongue 
50 4 
6 Yellow Colour urine 50 4% 
7 Constipation 41 Nil 
8 Diarrhoea  6 Nil 
9 Abdominal pain 8 Nil 
10 Puritus 50 Nil 
11 Irritability 50 Nil 
12 Liver tenderness 11 3 
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RESULTS AFTER TREATMENT
S.no Results
1 Good relief
2 Moderate relief
3 Mild relief
 
 
 
 
 
 
 
 
Results after treatment
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TABLE-16 
 
  
No.of cases percentage
 47 94%
 3 6%
 - - 
94%
6%
0%
 
 
 
 
 
Good relief
Moderate relief
Mild relief
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OP CASE LIST 
SL. NO O.P. NO Name Age/Sex No of days treated Results 
1. 52407 Raja 12mc 31 Good 
2. 52408 Jothi 8fc 21 Good 
3. 53669 Kumar 2mc 9 Good 
4. 53707 Subathra 7Fc 15 Good 
5. 53708 Baba 11mc 15 Good 
6. 53775 Dvaika 2FC 15 Good 
7. 55271 Pushbaraj 9mc 11 Good 
8. 57851 Saravanan 11mc 9 Good 
9. 63005 Vikki 2 ½ mc 12 Good 
10. 63006 Mathumitha 1 ½ FC 19 Good 
11. 63604 Vijay 6mc 17 Good 
12. 63645 Raja 9mc 17 Good 
13. 63680 Prasanna 9FC 13 Good 
14. 64936 Ameera Jeniya 2FC 8 Fair 
15. 67276 Bhagavathi 9FC 14 Good 
16. 67277 Bhavithra 6FC 14 Good 
17. 67673 Pooban 5mc 13 Good 
18. 67784 Sabiya 4FC 33 Good 
19. 68029 Nithya 2FC 30 Good 
20. 68042 Kalyana Kumar 12MC 30 Good 
21. 69714 Sakthi 12FC 21 Good 
22. 70172 Karthika 12FC 20 Good 
23. 72070 Sameeha 7FC 25 Good 
24. 72249 Ponni 12FC 45 Good 
25. 73545 Deepa 12FC 47 Good 
26. 77194 Daniel 11MC 16 Good 
27. 80170 Jesulin 12FC 36 Good 
28. 83535 Puvaneshvaran 10MC 16 Good 
29. 85584 Sakthivel 3 ½ MC 8 Good 
30. 100955 Fathima 12FC 9 Fair 
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TABLE SHOWING RESULTS 
SL 
NO 
IP 
NO 
Patient 
Name 
Age/s
ex 
DOA Signs and 
symptoms 
Neer 
kuri 
Neikuri Treatment 
Medicine 
DOD Total 
Days 
Treated 
Result 
1. 1840 Bavatharani 12FC 09.02.2
012 
Anorexia, 
Nausa,Vomi
ting, fever, 
Yellow 
coloured 
Urine and 
Sclera 
constipation, 
Abdominal 
Pain 
Yellow Ring karisalankanni 
churnam 5gms 
two timg/day 
with sugar 
16/12/
12 
8 Good 
2 1896 Biyula 11FC 15/12/1
2 
Fever, 
Nausa,Vomi
ting, 
Yellowish 
discolouratio
n of urine, 
Diarrhoea 
Yellow Ring karisalankanni 
churnam 5gms 
two timg/day 
with sugar 
18/02/
12 
4 Good 
3. 2392 Porselvi 12FC 24/07/2
012 
Loss of 
appetite, 
abdomen 
pain nor 
associated 
with 
Vomiting, 
Constipation
, Yellowish 
discolouratio
n of Urine 
Yellow Ring karisalankanni 
churnam 5gms 
two timg/day 
with sugar 
18/8/1
2 
15 Good 
4 2464 Vasthirani 12FC 28/7/20
12 
Nausea, 
Vomiting, 
Loss of 
appetitie, 
abdominal 
Yellow Ring karisalankanni 
churnam 5gms 
two timg/day 
with sugar 
13/8/1
2 
15 Good 
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Pain, 
Yellowish 
discolouratio
n of Urine. 
5 2644 Saravanan 11MC 10/08/2
012 
Fever, 
Vomiting, 
Abdomer 
Pain, Loss of 
appetite, 
Yellowish 
discolouratio
n of sclera, 
Urine, 
lethargy, 
Throat Pain 
Yellow Ring karisalankanni 
churnam 5gms 
two timg/day 
with sugar 
14/08/
12 
5 Good 
6. 2902 Vishnu 6mc 03/09/2
012 
Nausea, 
Vomiting, 
Abdominal  
Pain + in  
Rt. 
Hypochandri
um, Liver 
enlargement, 
Yellowish 
discolouratio
n of Urine 
Yellow Ring karisalankanni 
churnam 5gms 
two timg/day 
with sugar 
10/09/
12 
8  Good 
7. 3297 Joba 12FC 27/09/2
012 
Vomiting, 
Constipation
, Loss of 
appetitie, 
associated 
with 
abdominal 
Pain + in the 
rt 
hypochandri
um and 
epigastrium 
region, 
yellowish 
Yellow Ring karisalankanni 
churnam 5gms 
two timg/day 
with sugar 
02/10/
12 
6 Fair 
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discolouratio
n of Urine.  
Sclera, 
Lethargy 
8. 2391 Malathi 2FC 02/10/2
012 
Nausea, 
Vomiting, 
Loss of 
appetitie  
associated  
abdominal  
Pain, Loose 
Stools, 
lethargy, 
Yellowish 
discolouratio
n of Urine 
c 
Yellow Ring karisalankanni 
churnam 5gms 
two timg/day 
with sugar 
05/10/
12 
4 Good 
9. 3397 Banu 12FC 03/10/2
012 
Loss of 
appetite 
associated  
abdominal 
Pain, 
Constipation
, Yellowish 
discolouratio
n of Sclera, 
Cough, 
throat pain, 
headache 
wit
h 
Yellow Ring karisalankanni 
churnam 5gms 
two timg/day 
with sugar 
06/101
2 
4 Fair 
10. 3335 Sameeka 7FC 29/09/2
012 
Fever, 
Nausea, 
Yellowish 
discolouratio
n of Sclera, 
conjunctiva 
and Urine, 
Lethargy 
abdominal 
Yellow Ring karisalankanni 
churnam 5gms 
two timg/day 
with sugar 
08/10/
12 
10 Good 
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Pain + Rt. 
hypochondri
um 
11. 3336 Atheepa 12FC 29/09/2
012 
Anorexia, 
pruritus, 
passing clay 
coloured 
stools, 
yellowish 
discolouratio
n of sclera, 
conjuctiva, 
Urine, 
enlargement 
of liver 
Yellow Ring karisalankanni 
churnam 5gms 
two timg/day 
with sugar 
08/10/
12 
11 Good 
12. 3549 Sakthi 12FC 12/10/2
012 
loss of 
appetite, 
Vomiting 
associated 
with 
abdominal  
Pain, altered 
stools, 
Yellow 
discolouratio
n of 
Urine/Sclera
, lethargy, 
dyspnoea, 
Chest Pain. 
 
Yellow Ring karisalankanni 
churnam 5gms 
two timg/day 
with sugar 
20/10/
12 
7 Good 
13. 3633 Immanuvel 12mc 20/10/2
012 
Nausea, 
Vomiting, 
Loss of 
appetite, 
abdominal 
pain, altered 
stools, 
yellowish 
discolouratio
Yellow Ring karisalankanni 
churnam 5gms 
two timg/day 
with sugar 
28/10/
12 
9 Good 
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n of urine, 
sclera 
14. 3632 Daniel 12mc 20/10/2
012 
Fever, 
Nausea, 
Vomiting, 
Abdominal 
Pain + in the 
rt 
hypochondri
um, 
yellowish 
discolouratio
n of Sclera, 
Urine, 
Constipation
, Lethargy 
Yellow Ring karisalankanni 
churnam 5gms 
two timg/day 
with sugar 
28/10/
12 
9 Good 
15. 3663 Yashin 4MC 25/10/2
012 
Nausea, 
Vomiting, 
Loss of 
appetite asso  
 abdominal 
Pain, 
Yellowish 
discolouratio
n of Sclera, 
Urine, 
Lethargy, 
Pale colour 
stools, 
Cough, Cold  
c 
Yellow Ring karisalankanni 
churnam 5gms 
two timg/day 
with sugar 
02/11/
12 
9 Good 
16. 3642 Esthar 6FC 22/10/2
012 
Fever, 
Nausea, 
Loss of 
appetite 
associated 
with 
abdominal 
Pain, 
Passing glay 
Yellow Ring karisalankanni 
churnam 5gms 
two timg/day 
with sugar 
30/10/
12 
9 Good 
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coloured 
Stools, 
Pruritus, 
yellowish 
discolouratio
n of Urine, 
Sclera, 
Lethargy 
17. 3012 Samuvel 12MC 11/09/2
012 
Fever, 
anorexia, 
Nausea, 
Vomiting, 
Yellowish 
discolouratio
n of sclera, 
conjuctiva 
and Urine, 
Passing glay 
coloured 
Stools, 
abdominal 
Pain, Liver 
enlargement 
two finger, 
pruritus, 
Loss of 
appetite, 
lethargy 
Yellow Ring karisalankanni 
churnam 5gms 
two timg/day 
with sugar 
14/09/
12 
4 Good 
18. 3948 Farthana 11/2 
FC 
20/11/2
012 
Nausea, 
Vomiting, 
Yellowish 
discolouratio
n of Urine, 
Sclera, 
Abdominal 
Pain, 
Diarrhoea. 
Yellow Ring karisalankanni 
churnam 5gms 
two timg/day 
with sugar 
26/11/
12 
7 Good 
19. 3949 Reeppan 2MC 20/11/2
012 
Anorexia, 
Loss of 
appetite, 
Yellow Ring karisalankanni 
churnam 5gms 
two timg/day 
26/11/
12 
7 Good 
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Vomiting, 
abdominal 
Pain, 
Yellowish 
discolouratio
n of sclera, 
Urine, 
lethargy 
with sugar 
20. 4397 Ponni 12FC 18/12/2
012 
Fever, 
anorexia, 
Vomiting, 
abdominal 
discolouratio
n of sclera, 
Urine, 
Lonjuctiva. 
Yellow Ring karisalankanni 
churnam 5gms 
two timg/day 
with sugar 
22/12/
12 
5 Good 
 
 
CLINICAL INVESTIGATION BEFORE TREATMENT 
SI.No
. 
IP.NO Age/ 
Sex 
Date of 
Color 
Urine 
color  
Bile salt Bile 
pigment 
    Hb 
Gm/dl 
Serum 
Bilirubin 
Mgs 
SAP 
Mg% 
SGOT 
U/L 
SG
PT 
U/L 
HBs 
Ag 
1. 1840 12FC 9/2/12 Yellow Positive Positive 10.8 1.8 5 35 32 -Ve 
2. 1896 11FC 16/ 2/12 Yellow Positive Positive 8.5 2 8 42 37 -Ve 
3. 2392 12FC 24/7/12 Yellow Positive Positive 8 1.6 4 34 32 -Ve 
4. 2464 22FC 28/7/12 Yellow Positive Positive 11.5 1.8 5 30 29 -Ve 
5. 2444 11M
C 
10/8/12 Yellow Positive Positive 12.2 2.3 10 42 38 -Ve 
6. 2902 6MC 09/09/12 Yellow Positive Positive 9.2 1.9 6 40 35 -Ve 
7. 3297 12FC 27/09/12 Yellow Positive Positive 11.2 2.9 8 50 40 -Ve 
8. 2391 2FC 02/10/12 Yellow Positive Positive 10.5 3.5 9 48 45 -Ve 
9. 3397 12FC 03/10/12 Yellow Positive Positive 12.4 4.2 12 80 65 -Ve 
10. 3335 7FC 29/9/12 Yellow Positive Positive 11.8 2.8 8 75 60 -Ve 
11. 3336 12FC 29/9/12 Yellow Positive Positive 11.5 3.5 14 80 55 -Ve 
12. 3549 12FC 12/10/12 Yellow Positive Positive 11.5 3.7 12 80 60 -Ve 
13. 3633 12FC 20/10/12 Yellow Positive Positive 10.6 3.6 11 75 55 -Ve 
14. 3632 12M
C 
20/10/12 Yellow Positive Positive 10 2.0 9 50 45 -Ve 
15. 3642 6FC 22/10/12 Yellow Positive Positive 9.4 3.2 8 45 30 -Ve 
  
131 
 
16. 3663 4MC 25/10/12 Yellow Positive Positive 12 4.2 14 85 70 -Ve 
17. 3012 12M
C 
11/9/12 Yellow Positive Positive 8.5 2.2 6 45 38 -Ve 
18 3948 1½FC  20/11/12 Yellow Positive Positive 10.8 2 4 36 30 -Ve 
19. 3942 2MC 20/11/12 Yellow Positive Positive 11.4 1.4 4 35 28 -Ve 
20. 4327 12FC 18/12/12 Yellow Positive Positive 10.5 1.6 6 48 40 -Ve 
 
 
 
 
 
 
 
CLINICAL INVESTIGATION AFTER TREATMENT 
SI.No. IP.NO Age/Sex Date of 
Admission 
Urine color  Bile 
salt 
Bile 
pigment 
    Hb 
Gm/dl 
Serum 
Bilirub
in 
Mgs 
SAP 
Mg
% 
SGOT 
U/L 
SGPT 
U/L 
HBs 
Ag 
1. 1840 12FC 9/2/12 Normal Negati
ve 
Negative 12.4 0.9 4 25 22 -Ve 
2. 1896 11FC 16/ 2/12 Normal Negati
ve 
Negative 11 1.2 6 35 30 -Ve 
3. 2392 12FC 24/7/12 Normal Negati
ve 
Negative 10 1.2 3 26 24 -Ve 
4. 2464 22FC 28/7/12 Normal Negati
ve 
Negative 12.5 0.9 4 29 26 -Ve 
5. 2444 11MC 10/8/12 Normal Negati
ve 
Negative 12 1.5 7 38 30 -Ve 
6. 2902 6MC 09/09/12 Normal Negati
ve 
Negative 10 0.9 4 35 28 -Ve 
7. 3297 12FC 27/09/12 Normal Negati
ve 
Negative 11.8 1.5 6 40 30 -Ve 
8. 2391 2FC 02/10/12 Normal Negati
ve 
Negative 12.4 1.8 7 42 34 -Ve 
9. 3397 12FC 03/10/12 Normal Negati
ve 
Negative 13 1.8 8 50 38 -Ve 
10. 3335 7FC 29/9/12 Normal Negati
ve 
Negative 12.5 0.9 4 40 30 -Ve 
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11. 3336 12FC 29/9/12 Normal Negati
ve 
Negative 12 2.1 8 60 42 -Ve 
12. 3549 12FC 12/10/12 Normal Negati
ve 
Negative 10.5 1.6 6 65 40 -Ve 
13. 3633 12FC 20/10/12 Normal Negati
ve 
Negative 11 1.2 6 42 28 -Ve 
14. 3632 12MC 20/10/12 Normal Negati
ve 
Negative 11.4 0.8 4 36 28 -Ve 
15. 3642 6FC 22/10/12 Normal Negati
ve 
Negative 10 1.6 5 34 24 -Ve 
16. 3663 4MC 25/10/12 Normal Negati
ve 
Negative 12 2.9 8 62 54 -Ve 
17. 3012 12MC 11/9/12 Normal Negati
ve 
Negative 10 1.0 4 36 28 -Ve 
18 3948 1½FC  20/11/12 Normal Negati
ve 
Negative 12.6 0.9 3 28 22 -Ve 
19. 3942 2MC 20/11/12 Normal Negati
ve 
Negative 12.6 0.8 3 32 20 -Ve 
20. 4327 12FC 18/12/12 Normal Negati
ve 
Negative 11.3 0.7 4 36 28 -Ve 
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EXAMINATION OF THE ABDOMEN 
All patients’ abdomen were systematically examined by inspection, palpation 
and percussion. 
Inspection 
 In abdomen examination, the patient should be in erect or upright posture. 
The abdomen bulging, epigastric pulsation, colour of the skin, movement of the 
abdomen, any distended vein, position of the umbilicus and pigmentation of the 
abdominal wall were noted.  
In all patients 
 The shape pulsation of the abdomen are not present 
 No distended veins 
 No visible peristaltic movements 
 The Umbilical position is normal 
 The abdominal wall moved in respiration 
 The surface of the abdomen is soft. 
Palpation 
 Tenderness of liver 
 Enlargement of liver 
 Enlargement of spleen 
 Other palpable mass were noted. 
 Rigidities is not present in any patients 
 In 1 case the liver was enlarge in 3 fingers with tenderness. 
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 In 2 cases the liver was enlarge in 2 fingers with tenderness 
 In 8 cases the liver was enlarge in 1 finger 
 Spleen was not enlarge in any case. 
Percussion 
 Fluid thrill and dullness were not present. 
Diagnosis 
 Diagnosis was made on the basis of eight types of investigation. 
 The Symptoms are, 
 Fever 
 Nausea 
 Vomiting 
 Anorexia  
 Weakness 
 Yellow coloration of sclera, Conjunctiva, Urine and Tongue 
 Tenderness present in the Rt hypochondrium 
 Iritability were noted and diagnosed as Manjal Kamalai. 
To confirm the diagnosis of patients 
 Age 
 Social status 
 Season 
 Place 
 Modern laboratory facilities are to be taken for diagnosis. 
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Treatment 
 All 50 cases were treated with 
1. Karisalankani churanam  
1 - 5 years    : 3 grms 2 times with white sugar per day. 
6- 12 years   : 5 grms 2 times with white sugar per day. 
 
Result 
 Among 50 patients, 38 patients relived by their complaints with in 5 
days and 12 patients were relived by their complaints within 10-15 days. 
Clinical symptoms 
 The progress was observed by important clinical features Viz, 
 Fever 
 Yellow coloured urine 
 Nausea 
 Flatulence 
 Tiredness 
 Pain in Rt hypochondric redion 
Objectives signs 
 In 85% of the cases is disappearance of yellow colouration of urine, 
Sclera and conjunctiva. 
 Then in 50 cases of Manjal Kamalai the following observations were 
recorded from the result of treatment. 
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SUMMARY 
 In India there are many existing predisposing factors which produce 
jaundice. Economically poor social status and literacy are mainly responsible 
for the poor knowledge about Jaundice. 
          Manjal Kamalai, a pitha type of disorder with considerable involvement 
of liver and gall bladder and wide constitutional feature was taken for this study. 
          Improper Hygienic measures like unpreserved water supply and drainage 
system in most places and improperly preserved food items, comtaminated 
needles and blood products favour the spread and development of this disease. 
  Accurate labeling of Jaundice in every case is essential to study the nature 
and to take preventive measures. 
 Among 50 patients admitted, 42 patients had given a history of contact 
with infected persons, 8 patients had taking excessive spicy, sour and pungent 
taste items. So Increased Pitha Kutram and them affected normal function of 
liver and it produced jaundice. 
  The clinical feature of the manjal kamalai resembles the clinical 
entity of infective hepatitis, discussed in varios literature collected in siddha and 
modern side dealing with the disease. 
 50 cases were admitted for study in the In-patient department. Amoung 
the patients 20 were Male and 30 were female. 
 The diagnosis of this  disease were made on the basis of eight types of 
clinical investigation, and mukkuttram mentional in siddha literature with 
concurrent practical application of modern clinical and laboratorical approach. 
 The important observation during this study has been shown that no 
patients were developed or reported any features of further complications like 
coma, Intestinal hemorrhage etc. 
  
140 
 
 The occurrence of this disease was marked in kaar, Koothir and 
mudhuvenil kalam. 
 The common belief of the publc is that the siddha medicines and diet 
prescribes are more effective in the treatment of manjal kamalai is once again 
established by the clinical study. 
 The cost of the medicine used in the treatment of jaundice is very low, 
that is very cheap when compared with the cost of other medicine s used in the 
treatment of jaundice. 
 The adverse side effect are nil in the treatment of jaundice by the Siddha 
Medicine. 
 
 
“TODAY’S CHILDREN ARE THE LEADERS OF TOMORROW” 
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ANNEXURE I  
PREPARATION &PROPERTIES OF  
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TRIAL DRUGS 
 
                    lR<st<!gilijz< << << <  
INGREDIENTS OF TRIAL DRUG: 
KARISALANKANNI CHURNAM  
Karisalankkani Samoolam  - 800gm 
Athimathuram    - 200gm 
Elam      - 200gm 
Thirikadugu     - 200gm 
Thiribala     - 200gm 
Thalisapathiri    - 200gm 
Kothumalli Vithai   - 200gm 
Maramanjal     - 200gm 
Mookirattai     - 200gm 
Seeragam     - 200gm 
Karunjeeragam    - 200gm 
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Method of preparation: 
All the above ingredients are ground well into fine powder and filtered by 
cloth (Vasthirakayam). 
 
DOSAGE: 
1-5yrs  3gms two times / day 
6-12 yrs  5gms two times / day 
 
Adjuvant :white sugar 
Vehicle: Honey 
Indication: MANJAL KAMALAI, PANDU, SOBAI 
Reference: CIKITCHARATNA DEEPAM II PART VAITHIYA   
  CINTHAMANI PAGE NO:162 
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(ECLIPTA PROSTRATA) 
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(GLYCYRRHIZA GLABRA)                  (SACCHARUN OFFICNARUM) 
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(PHYLLANTHUS EMBLICA)                                                           (PIPER LONGUM)!
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         (NIGELLA SATIVA)                                 (PIPER NIGRAM) 
                 
 
 
 
 
 
 
 
 
  
151 
 
 
 
 
PROPERTIES OF TRIAL DRUG 
lR<st<!giqsijz!;< << << < !
Botanical Name  : Eclipta alba 
Family   : Asteraceae 
Suvai    : Kaippu 
Thanmai   : Veppam 
Pirivu    : Karuppu 
Part Used    : Whole Plant 
   
  The herb has been known for its curative properties and has been 
utiliszed as antihepatotoxic, antihaemorrhagic, analgesic, antibacterial, 
antioxidant, immunomodulatory properties and it is considered as a good 
rejuvenator too. 
 
  It is used as a tonic and diuretic in hepatic and spleen enlargement.  
It is also used in catarrhal jaundice and for skin disease.   
   
The alcoholic extract of the plant has shown antiviral activity against 
virus.  The fresh juice of leaves is used for increasing appetite, improving 
digestion and as a mild boel regulator.  It is commonly used in viral hepatitis to 
promote bile flow and protect the parenchyma. 
   
It is widely used in India as a  chologoague and deobstrutent in hepatic 
enlargement, for jaundice and other ailments of the liver and gall bladder. 
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Parts Chemical Constituents 
Leaves Wedelolactone [1.6%], 
desmethylwedalolactone, 
desmethylwedalolactone-7-glucoside, 
Stigmasterol 
Roots Hentriacontanol, Heptacasnol & 
Stigmasterol, Ecliptal, Eclalbatin 
Aerial Parts P-amyrin & luteolin-7-0-
glucoside,Apigenin,cinnaroside,sulphur 
compound, Eclalbasaponin I-VI 
Stems Wedelolactone 
Seeds Sterols, Ecliptalbine (alkaloid) 
Whole Plant Resin, Ecliptine, reduing sugar, 
Nictonine, Stigmasterol, Triterpene, 
Saponin, Eclalbatin, Ursolic acid, 
oleanolic acid. 
Pharmacological activities of the chemical Consittuents 
Chemical Constituents Pharmacological activities 
Wedelolactone Antihepatotoxic, Antibacterial, 
Trypsin inhibitor, Antivenom 
Eclalabasaponins Hair revitalizing, Antiproleferative,  
Demethyl Wedelolactone Antihepatotoxic, Antihaemorrhage, 
Antivenom, dye 
Dasyscyphin c Antiviral, Anticancer 
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Eclalbatin Antioxidant 
Ecliptalbine, verazine Lipid lowering, Analgesic 
!
!
!
lR<st<!< << << < giqsijzohiKG{l<;<<< !
“Gvx<gl<lz<!gilijzGm<moliMOsijh!
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!jgbif<!kgjvobik<kg<!giz<”/!!
! ! ! ! ! ! ! .ngk<kqbi<!G{himl<!< < << < << < < !
nkqlKvl<<<<!
BOTANICAL NAME : GLYCYRRHIZA  GLABRA 
 FAMILY                  : Papilionacease 
Suvai    : Inippu 
Thanmai   : Seetham 
Pirivu    : Inippu 
Part Used    : Peeled root 
 
CHEMICALCONSTITUENT: 
Glycyrrhecticacid,glabridin,triterpenoid,Saponin,gycyrrhetinicacid,glucur
onicacid,licoagrodin,licoagrochalconesb,c,d,licochalconeC,kanzonoly,glyiniani
nB,liquiritigeninglycosides,isoliquiritigeninglycosides. 
ACTION                  :Antiviral, 
                                Gastroprotective 
MEDICINALUSES: 
Frequently employed for stomach problems ,       
          for indigestion and liver problems . 
“hqk<kolZl<!HVg<gqgqiqs<svl<!Nui<k<k!
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Botanical Name  : zingiber officinale 
Family   :  zingiberaceae  
Suvai    : Karppu 
Thanmai   : Veppam 
Pirivu    : Karpu 
Part Used    : Rhizome 
 
CHEMICAL CONSTITUENT: 
                      Gingerol,shoagoles and ,sesquiterpenes,bisabolene 
zingiberene,zingiberol,curcumene,monoterpenes,geranial. 
ACTION                    :   Heating appetizer 
MEDICINAL USES    : Gingerols increase the motility of the gastro 
intestinal tract and have analgesics,sedatives,antipyretics and antibacterial 
properties. 
               Intestinal disorders such as indigestion  
               Abdominal pain due to intestinal upset 
               Pale complexion and strengthen the body after blood loss. 
 
! “Okiml<!N!ll<Ohig<GR<!Sg<G” 
 
gMg<gib<!< << << <  
BOTANICAL NAME    : TERMINALIA CHEBULA 
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FAMILY                 : COMBRETACEAE  
Suvai    : Inippu, kaippu, thuvarpu, karppu, pulippu  
Thanmai   : Veppam  
Pirivu    : Inippu  
 
CHEMICAL CONSTITUENT: 
Gallic acid,chebulagic acid,chebulinic acid,triterpenoid 
glycosides,arjunolic acid,terminolic acid,punicalagin,corilagin,neochebulinic 
acid,flavonol glycosides,triterpenoids,coumarin,anthroquinone,sennoside.  
!
 “K~zlqc!H{<uik!Osi{q!gilijzbqv{<!
!mizlqc!Ohil<uiqg<g!gibiz<”!
sQvgl<Q <Q <Q <!
BOTANICAL NAME    :CUMINUM CYMINUM 
FAMILY                          :UMBELLIFERAE  
Suvai    : Inippu  
Thanmai   : Thatpam  
Pirivu    : Inippu  
Part Used    : Seeds  
 
CHEMICAL CONSTITUENTS: 
pinene,1,8-cineole,linalool,sesquiterpenoid 
glucosides,cuminosideA,cuminosideB,methyl-d-erythritol,alkyl glycosides 
Hentria Contanal ,14- hepta consanol and  stigmasterol isolated from roots –
Journal of Indian chemical society 1982,59,905.  
 
ACTION               :stomachic 
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MEDICINAL USES: whole plant is tonic and deobstruent is hepatic& spleenic 
enlargement.Plant juice is combination with aromatics is administered for 
Catarrh  and jaundice. 
              -Indian material medical by nadkarini 1992,472  
               Jeera water frequently relieves indigestion and flatulence 
!
gVR<sQvgl<< Q << Q << Q <!
BOTANICAL NAME    : NIGELLA SATIVA 
FAMILY                    : Ranunculaceae  
Suvai    : Kaippu  
Thanmai   : Veppam  
Pirivu    : Karppu  
CHEMICAL CONSTITUENTS: 
Seeds contain Protein 26.7%,Carbohydrates 40%,thymoquinone, 
nigellone, nigellidine. 
ACTION              :Anthelminthic, diuretic      
MEDICINAL USES: Decoction of seeds especially used for intestinal worms. 
!
kie<xqg<gib<;< < << < << < < !
BOTANICAL NAME     : TERMINALIA BELLARICA 
FAMILY                          : COMBRETACEAE  
Suvai    : Thuvarppu  
Thanmai   : Veppam  
Pirivu    : Inippu  
 
CHEMICAL  CONSTITUENTS: 
Gallic acid,ellagic acid,chebulagic acid,ethyl gallate,glucose. 
ACTION               :Tonic,expectorant  
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MEDICINAL USES :Fruit used in the preparation TRIPHALA, used for 
liver disease ,gastro intestinal complaints,purgatives. 
!
kqh<hqzq<<< !
BOTANICAL NAME      : PIPER LONGUM 
FAMILY                    : PIPERACEAE 
Suvai       : Inippu  
Thanmai      : Thatpam  
Pirivu       : Inippu  
 
CHEMICALCONSTITUENTS: 
Fruit-Guineensine,pipernonaline,pellitorine,piperanine,brachyamide A, 
brachyamide B & brachystine. 
Root- Piperlongumine,piperlingumine &  Sesamine. 
ACTION             : Fruit acts as an analgesic,diuretics,relaxes muscle tension & 
allevation of anxiety . 
MEDICINAL USES: 
Fruit used in the preparation TRIKATUGU, used for kapha disease, 
especially respiratory tract infections-cough, bronchitis, asthma, enlargement of 
liver and other abdominal disturbance. 
Pipalli is beneficial as a brain tonic &  disease of Vatha. 
 
lz<zq;<<< !
BOTANICAL NAME   :CORIRIANDER SATIVUM  
FAMILY                   : APIACEAE  
Suvai    : Karppu  
Thanmai   : Seetha veppam  
Pirivu    : Karppu  
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CHEMICAL  CONSTITUENTS:  
Antioxidant Compounds- B Carotene, B-Cryptoxanthin epoxide,Lutein -
5,6- epoxide ,Coriandrones A,B,C,D,E,.isocoumarins,coriandrin. 
Coriander fruits- quercetin 3 –glucuronide,isoquercitrin,Rutin 
ACTION              : 
Fruits are aromatic,Anti-inflammatory. 
MEDICINAL USES: Seeds are used as drug for indigestion,against 
worms,rheumatism & Pain in  joints  . 
Powdered seeds decoction or infusion –dyspeptic Complaints,loss of 
appetite,Convulsion,insomnia & anxiety. 
!
lvlR<st<;< << << < !
BOTANICAL  NAME  : COSCINIUM FENESTRATUM  
FAMILY                         : MENISPERMACEAE  
Suvai    : Kaippu  
Thanmai   : Vetppam  
Pirivu    : Karppu  
 
CHEMICAL CONSTITUENTS :  
Stem-Berberine,Protoberberine. Roots-berlamine, dihydroberlamine, 12, 13-
dihydro-8-oxoberberine, oxyberberine. 
ACTIONS: Stomachic,tonic. 
MEDICINAL USES : Powdered stem is dissolved  in milk and given for 
jaundice,fever,abdominal disorders,general debility . 
 
lqtG;!
BOTANICAL  NAME  : PIPER NIGRUM   
FAMILY                     : PIPERACEAE  
Suvai    : Karppu  
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Thanmai   : Vetpam  
Pirivu    : Karppu  
 
CHEMICAL CONSTITUENTS : 
         Fruit –isopiperolein B, Piperine, piperidine, Pipercide, pellitoroin, 
pellitorine. 
            Essential oil- Eugenol, myristicin,B –bisabolone,limonene,Phenyl ether, 
myristicin . 
ACTIONS: Stimulant, antipyretic,expectorant,Carminative. 
MEDICINAL USES :  
Proliferation and primary seeds is used for liver necrosis,biliary 
hepatomas and Viral hepatitis,sore throat  and Cold. 
 
“giKOfib<!likIGe<lr<!gilijz!lf<kole<xQI” 
!
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BOTANICAL  NAME  :BOERHAAVIA DIFFUSA  
FAMILY                         :NYCTANGINACEAE   
Suvai    : Kaippu  
Thanmai   : Vetppam  
Pirivu    : Karppu  
 
CHEMICAL CONSTITUENTS : 
            Punarnavoside,B-sitosterol, tetracosanoic, ursolic acid. 
ACTIONS:  
             hepato protective,anti –inflammatory, antipyretics,analgesics,antiviral 
and anti- bacterial activity ,expectorant,carminative. 
MEDICINAL USES : Roots used in treatment of jaundice. 
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        Brazil`s leading medical herbalists reports Erva tostao is a plant medicine 
of great importance  extra ordinarily beneficial in the treatment of liver 
disorders . It is employed  in Brazillian ,herbal medicine to stimulate the 
emptying of  gall bladder ,as a diuretic for all types of liver disorders ,(including 
jaundice and hepatitis ) gall bladder and stones urinary tract disorders, renal 
disorders . 
       In herbal  medicine systems in India the roots are employed as a 
diuretics,digestive laxative,internal inflammation of all 
kinds,oedema,jaundice,menstrual problems,anaemia ,liver ,gall bladder and 
kidney disease . Throughout the tropics ,Erva tostae is Considered an excellent 
natural remedy for guinea worms. 
           The novel alkaloids found in Erva tostae have been documented with 
immune modulating effects . 
       In One study the alkaloid fraction of the root evidenced a dramatic effect 
in reducing an elevation Cortisol levels under stressful conditions(Cortisol is an 
inflammatory chemical produced in the body in an immune response ) 
Boerhaavic acid, borhavine, heptadecyclic acid ,histidine  
,punarnavine.sitosterols and stigmasterol are present  .Erva tostae  has long been 
used in traditional medicine systems as  a diuretic. 
In Traditional preparation for a general liver tonic . 
gVl<H<<< !
Botanical Name: Saccharum officnarum 
Family : Poaceae 
Suvai  : Inippu 
Thanmai : Seetham 
Pirivu  : Saccharum juice, Suger 
ACTION: 
 Antiseptic 
 Demulcent 
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CONSTITUENTS:- 
 Sachearine, matter, water, mucilage, resin Fat, albumin and Vit C. 
 It is a good remedy In cough, hiccough, apthae and hoarseness and 
locally in granulation of the eyelids and cornea. It is chiefly used as a vehicle to 
disguise the taste of various nauseous medicines and chiefly of medicines given 
to children. 
 It is largely used as a perservation and antiseptic to protest active 
ingredient and certain iron preparation against oxidation and putrefaction but 
not against fermentation.  
 
“sQeq!gVg<gjvg<Gk<!kQvik!ue<SvLr<!
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BOTANICAL  NAME   : Eletaria Cardamomum          
Family   :  Scitaminaceae 
Suvai    : Karppu 
Thanmai   : Veppam 
Pirivu    : Karppu 
Part used   : Dried type seeds 
 
ACTIONS: Stimulant ,carminative,stomachic  
 
CHEMICAL CONSTITUENTS : 
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 It contains free eugenal [70-90%] eugenolaretate [2-17%] and 
caryophyllene are its constituents. When used externally, mthe oil is 
Rubefacient and Internally it has carminative and antispasmodic action. 
!
!
!
!
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kitqshk<kqiq<<< !
! Botanical Name  : Taxus buccata 
 Family   : Taxacea 
          Suvai                       : Karppu 
          Thanmai                  : Veppam 
          Privu                       : Karppu 
          Part used                 : Leaf 
!
kqiqhzi!
Belleric Myrobalan   - Gallotannnic acid, colouring matter, Resins,   
             Greenish yellow oil, Terpenes, Sterols, Phenols.!
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Chebullic Myrobalan - Chebulinic acid, Gallic acid, Tannic acid, Brownish 
      yellow colouring matter, Resin. 
Phyllanthus emblica  -    Rich in vitamin C 
 
 
 
kqiqhziohiKG{l<;<<< !
“uqk<kqvkqfisqOfib<!ou{<Gm<ml<!Nseh<H{<!!
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!
! Tripala is used as a laxative and in enlarged liver, stomach complaints 
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ANNEXURE II 
BIO – CHEMICAL ANALYSIS 
 
                    lR<st<!gilijz< << << <  
 
BIO -CHEMICAL ANALYSIS OF 
KARISHALANKANNI CHURNAM 
PREPARATION OF THE EXTRACT 
 5 gms of the drug was weighed accurately and placed in a 250ml clean 
beaker.  Then 50ml of distilled water is added and dissolved well.  Then it is 
boiled well for about 10 minutes.  It is cooled and filtered in a 100ml volumetric 
flask and then it is make up to 100ml with distilled water.  This fluid is taken for 
analysis. 
QUALITATIVE ANALYSIS 
S. 
NO. 
EXPERIMENT  OBSERVATION  INFERENCE 
1)  TEST FOR CALCIUM: 
2ml of the above prepared 
extract is taken in a clean test 
tube.  To this add 2ml of 4% 
Ammonium oxalate solution. 
A white precipitate 
is formed. 
Indicates the 
presence of 
calcium 
2)  TEST FOR SULPHATE: 
2ml of the extract is added to 
No white precipitate 
is formed. 
Absence of 
sulphate  
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5% barium chloride solution. 
3)  TEST FOR CHORIDE 
The extract is treated with 
silver nitrate solution. 
No white precipitate 
is formed 
Absence of 
Chloride 
4)  TEST FOR CARBONATE: 
The substance is treated with 
concentrated Hcl. 
No brisk 
effervescence is 
formed. 
Absence of 
carbonate 
5)  TEST FOR STARCH: 
The extract is added with weak 
Iodine solution. 
Blue colour is 
formed. 
Indicates the 
presence of 
starch 
6)  TEST FOR IRON : 
FERRIC: 
The extract is acidified with 
glacial acetic acid and 
potassium ferro cyanide. 
No blue colour is 
formed. 
Absence of 
ferric Iron. 
7)  TEST FOR IRON: 
FERROUS: 
The extract is treated with 
concentrated Nitric acid and 
ammonium thio cyanide 
solution. 
Blood red colour is 
formed 
Indicates the 
presence of 
ferrous Iron. 
8)  TEST FOR PHOSPHATE: 
The extract is treated with 
ammonium Molybdate and 
concentrated nitric acid. 
No yellow 
precipitate is 
formed 
Absence of 
phosphate 
9)  TEST FOR ALBUMIN: 
The extract is treated with 
Esbach’s reagent 
No yellow 
precipitate is 
formed 
Absence of 
Albumin 
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10) TEST FOR TANNIC ACID: 
The extract is treated with 
ferric chloride  
Blue black 
precipitate is 
formed 
Indicates the 
presence of 
Tannic acid 
11) TEST FOR 
UNSATURATION: 
Potassium permanganate 
solution is added to the extract 
It gets decolourised Indicates the 
presence of un 
saturated 
compound. 
12) TEST FOR THE 
REDUCING SUGAR: 
5ml of Benedict’s qualitative 
solution is taken in a test tube 
and allowed to boil for 2 mins 
and add 8-10 drops of the 
extract and again boil it for 2 
mins. 
No colour change 
occurs 
Absence of 
Reducing 
sugar. 
13) TEST FOR AMINO ACID: 
One or two drops of the extract 
is placed on a filter paper and 
dried it well.  After drying, 1% 
Ninhydrin is sprayed over the 
same and dried it well. 
Violet colour is 
formed 
Indicates the 
presence of 
Amino acid 
14) TEST FOR ZINC: 
The extract is treated with 
potassium Ferrocyanide 
No white precipitate 
is formed 
Absence of 
Zinc 
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ANNEXURE III 
PHARMACOLOGICAL ANALYSIS 
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PHARMACOLOGICAL ANALYSIS 
HEPATO – PROTECTIVE STUDY OF KARISALANKANNI      
      CHURNAM 
AIM: 
 To groups of albino rats each consisting of 3 rats were used in this study. 
One group (A) of Albino rats received CCL4 0.2 ml/100mg body weight 
subcutaneously. The Second group (B) received CCL4 0.2ml/ 100mg body 
weight with trial drug KARISALANKANNI CHURNAM for 8 days 
continuously. 
 On the ninth day the animals were sacrificed and liver lobes excised for 
histopathological studies. 
Histopathological studies 
In the CCL4 given group there was marked liver damage. Both the 
sample liver shows hepatocytes with lobular disarry. There is ballooning of the 
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cytoplasm with plenty of fat vacuoles. In focal areas that coalesce to form fatty 
cysts. Few of the hepatocytes are completely replaced by fat vacuoles. Minimal 
fibrosis was seen extending from portal tract. 
In group that received CCL4 and drug an over all protection from CCL4 
damage was observed. Both the liver section shows normal hepatocytes 
arranged around central vein with mild dilation. Sinuses appear dilated with 
prominent kupffer cells. Protal tracts appear expanded. 
These two group of liver section were compare to the normal histological 
appearance of the rat liver. 
IMPRESSION 
1. Group A: Moderate to severe fatty changes. 
2. Group B: Non specific changes. 
CONCLUSION 
             The test drug have hepato-protective action aginst CCL4 induced liver 
damage. 
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HISTOPATHOLOGY OF LIVER -  NORMAL 
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HEPATO PRODECTIVE STUDY ON RATS 
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IMPRESSION 
LIVER  IN  JAUNDICE 
 
CONCLUSION:  
  The test drug have significant hepato protective action. 
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ANTI – PYRETIC STUDY OF KARISALANKANNI 
CHURNAM 
AIM: 
       To study anti – pyretic activityof KARISALANKANNI CHURNAM. 
PROCEDURE: 
            Group of six Albino rats were selected and divides equally into 2 groups 
all the rats were made hyperthermic by subcutaneous injection of  12% 
suspension of yeast at a dose of 1ml/100 ml of body weight 10hrs later one 
group of animals was given the test drug by gastric tube the dose of 2ml. 
             The meal rectal temperature for two groups were recorded at 0 hr, 11/2 
hrs and 41/2 hrs after the drug administration .  The difference between the 
mean temperature of the control group and that of  and the other group was 
measures. 
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STUDY OF ANTI -PYRETIC ACTION 
BY HIND PAW METHOD 
USING PLETHYSMOGRAPH USING THE DRUG ON ___ 
KARISALANKANNI CHOORANAM 
 
Sl 
No. 
Name of 
Drug/Groups 
Dose/100 
Gram 
body 
weight 
Initial 
Temperature 
In 
Centigrade 
        After Drug 
administration  
Remarks 
 
 
 
 
Significant 
Action 
1 ½ Hour 3.0 
Hour 
4 ½ 
Hour 
1. Control (Water) 1ml 37.5 
37.5 
38.0 
38.0 
38.5 
38.5 
38.5 
38.5 
2. Standard ( Glur 
Brufer) 
20 mg 37.0 
37.0 
36.0 
36.0 
35.0 
35.0 
34.0 
34.0 
3. Drug 2 ml 37.0 
37.0 
36.0 
36.0 
35.0 
35.0 
34.5 
34.5 
 
INFERRENCE: The test drug has significant action in anti -pyretic action 
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ACUTE ANTI-INFLAMMATORY ACTION KARISALANKANNI 
CHURNAM 
AIM 
To study the anti-inflammatory effect of “Karisalankanni churnam” 
PEPARATION OF TRIAL MEDICINE 
 1gm of the Karisalankanni churnam was taken and dissolved in 100ml of 
hot water. A dose of 1ml was given to each rat. This 1ml contains 100mg of the trial 
medicine. 
PROCEDURE 
 The anti-inflammatory activity of  Karisalankanni churnam” was studied 
in healthy albino rats weighning 100-150gm. Nine rats were collected and divided into 
three groups each containing three rats.  
 First group was kept controlled by giving distilled waster of 2ml/100gm of 
body weight. The second group was given Ibuprofen as dose of 20mg/100gm of body 
weight. The third group received the trial medicine Karisalankanni churnam 
of 65mg/100gm of body weight. 
 Before administration of trial medicine, the hindpaw volume of all rats were 
measured. This was done by dipping the hindpaw upto tibiotarsal junction, into 
mercury plethysmography. While dipping the hindpaw, by pulling the syringe piston, 
the level of mercury in the centre small tube was made to coincide with red marking 
and reading was noted from the plethysmograph. 
Soon after the measurement, the medicines were administered orally. Once 
hour later, a subcutaneous injection of 0.1ml of 1% (W/V) carrageen in water was 
made into plantar surface of both hind paw of each rat. 
 Three hours after carrageenin injection, hindpaw volume was measured once 
again. The difference between the initial and final volume was calculated and 
compared. 
 This method is more suitable for suitable the anti-inflammatory activity in 
acute inflammation. The values are given in the table. 
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STUDY OF ACUTE ANTI-INFLAMATORY 
BY HIND PAW METHOD 
 
Using plethysmograph using the drug on ___ Karisalankanni Chooranam 
 
Sl 
N
o. 
Name of 
Drug/Gro
ups 
Dose/1
00 
Gram 
body 
weight 
Initial 
Readi
ng 
avera
ge 
Final 
Readi
ng 
Avera
ge 
Mean 
Differe
nce 
Percentag
e 
Inflamma
tion 
Percent
age 
Inhibiti
on 
Rema
rks 
1. Control 
(Water) 
2ml 0.55 1.4 0.85 100 -  
2. Standard 
( Glur 
Brufer) 
20 mg 0.55 0.75 0.20 23.5 76.5  
3. Drug 100 
mg 
.625 1.0 0.375 44.1 55.g.  
 
INFERRENCE: The test drug has significant action in anti -inflammatory action 
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PHARMACOLOGICAL ANALYSIS OF Karisalankanni 
churanam 
                  STUDY ON HAEMATINIC ACTION 
Preparation of the trail drug: 
 
                             Varieties of preparations in siddha system of medicine are 
well known for its haematinic action of which Karisalankanni churanam To 
prove the efficacy of this medicine, an attempt was made to study its effect 
using “Albino rats”. For this purpose, rats were made anaemic by the following 
procedure. 
 
Artificially induced Iron deficiency:  
 
                         The albino rats taken for this experiment were kept in 
aluminium cages and provided with drinking water and milk, free from iron. 
The administration of the iron preparation under investigation was started, when 
the haemoglobin level fell to nearly 6.0 gm/100ml. At the beginning of the 
experiment 40% was determined.  
 
Study on rats:  
                     
                      Twelve albino rats were first divided into equal groups, with six 
rats in each group. The first group received water. The second group received. 
Karisalankanni churnam All the above procedures were continued for four 
weeks at the rate of once in a day. The Haemoglobin levels of rats were 
measured after 1 week, 2 week, 3 weeks and 4 weeks. The results observed are 
tabulated in the following chart 
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STUDY OF HAEMATINIC ACTION 
Serial 
No. 
Drugs Dose Before drug 
Administration 
After Drug 
administration 
Remarks 
 
 
 
1. 
 
 
Control 
(Water) 2ml 
 INITIAL 
READING 
Ist 
WEEK 
II 
WEEK 
III 
WEEK 
IV 
WEEK 
V 
WEEK 
   
 
 
 
 
Significant  
Action 
5.8 
6.2 
6.0 
6.4 
6.2 
6.5 
5.8 
6.2 
6.0 
6.4 
6.2 
6.5 
5.6 
6.0 
5.7 
6.1 
6.0 
6.2 
5.5 
6.0 
5.6 
6.0 
5.9 
6.1 
5.3 
5.7 
5.3 
5.7 
5.6 
5.8 
5.2 
5.5 
5.1 
5.5 
5.5 
5.6 
 
2 Karisalankanni 
Chooranam 
 60 
6.2 
6.4 
6.4 
6.0 
5.9 
6.0 
6.2 
6.4 
6.4 
6.0 
5.9 
6.3 
6.5 
6.7 
6.7 
6.2 
6.2 
7.0 
7.0 
7.2 
7.3 
7.0 
7.0 
8.0 
8.2 
8.4 
8.4 
8.5 
8.0 
9.5 
9.6 
9.7 
9.9 
9.4 
9.2 
10.6 
10.5 
10.7 
10.5 
10.6 
10.6 
 
  
 
INFERRENCE: The test drug has significant action in Haematinic action 
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PROFORMA OF CASE SHEET 
GOVERNMENT SIDDHA MEDICAL COLLEGE 
PALAYAMKOTTAI-THIRUNELVELI-627 002. 
Br.IV KUZHANTHAI MARUTHUVAM POST GRADUATE 
DISSERTATION STUDY ON “MANJAL KAMALAI” 
ward  :     Place of birth : 
Ip.No  :     religion  : 
Bed No :     Nationality  : 
Name  :     Admitted on time : 
Age  :     Discharge on time : 
Sex  :     Diagnosis  : 
Father’s Name :     Medical officer : 
Occupation : 
Income : 
Address : 
Informant : 
Complaints and duration 
History of present illness 
History of previous illness 
Birth History 
1. Antenatal history  : 
2. Prenatal history  : 
3. Neo natal history  : 
Development history    : 
Nutritional history    : 
Immunization    : 
Family history    : 
Environmental and social history : 
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SIDDHA ASPECT 
GENERAL CONDITION ON ADMISSION 
GENERAL APPEARANCE 
CONDITION OF 7 UDAL KATTUGAL: 
1. Saram 
2. Sennear 
3. Oon 
4. Kozhuppu 
5. Enbu 
6. Moolai 
7. Sukkilam / Suronitham 
ENNVAGAI THERVUGAL 
1. Naa 
2. Niram 
3. Mozhi 
4. Vizhi 
5. Malam 
6. Moothiram 
7. Sparism 
8. Nadi 
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MUKKUTTRANGAL 
I. Vatham 
1. Piranan 
2. Abanan 
3. Viyanan 
4. Udhanan 
5. Samanan 
6. Nagan 
7. Koorman 
8. Kirugaran 
9. Devathathan 
10. Dhananjeyan 
I. PITHA 
1. Anilam 
2. Ranjagam 
3. Sathagam 
4. Prasagam 
5. Alosagam 
II. KABAM 
1. Avalambagam 
2. Kilethagam 
3. Pthagam 
4. Tharpagam 
5. Santhigam 
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KANMAENTHIRIYANGAL 
1. Kai 
2. Kal 
3. Vai 
4. Eruvai 
5. Karuvai 
PORI PULANGAL 
1. Sound (Ear) 
2. Light (Eye) 
3. Sensation (Skin) 
4. Taste (Tongue) 
5. Smell (Nose) 
GUNAM 
1. Sathuva Gunam 
2. Raso Gunam 
3. Thamo Guman 
MUMMALAM 
1. Malam 
2. Moothiram 
3. Viyarvai 
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NILANGAL 
1. kurinji 
2. Mullai 
3. Marutham 
4. Neithal 
5. Palai 
PARUVA KALANGAI 
1. Kaar 
2. Koothir 
3. Munpani 
4. Pinpani 
5. Illavenil 
6. Mudhuvenil 
NEER KURI 
NEI KURI 
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MODERN ASPECTS 
GENERAL EXAMINATIONS: 
Height 
Weight 
Head circumference 
Mid arm circumference 
General appearance 
State of nutrition 
Skin colour 
Cyanosis 
Jaundice 
Pallor 
Erythema 
Lymphadenopathy 
Clubbing 
Pedal oedema 
Vital Signs 
 Temperature 
 Pluse rate 
 Respiratory Rate 
 Blood pressure 
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 Systemic Examination 
1. Examination of the abdomen 
a) Inspection: Size, shape, distended veins, position of umbilicus 
b) Palpation: Liver, spleen, Gallbladder and tenderness. 
c) Percussion: Fluid Hrill, 
d) Auscultation: Bruits or Bowel sings 
EXAMINATION OF OTHER SYSTEM: 
 CVS 
 RS 
SPECIAL INVESTIGATIONS 
Total W.B.C count: 
Differential W.B.C count: 
Erythrocyte sedimentation Rate: 
Hemoglobin percentage   
Total serum bilirubin 
Direct   : 
Indirect : 
Total serum protein 
Australian Antigen (HBs Ag) 
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LIVER FUNCTION TEST 
ALT 
AST 
SAP 
X-RAY: 
plain Abdomen 
URINE: 
Albumin 
Sugar 
Bile salts 
Bile pigments 
MOTION 
 Color 
 Ova 
 Cyst 
 Occult blood 
TREATMENT: 
ADVICE 
PROGRESS OF THE PATIENT: 
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   GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
                 PALAYAMKOTTAI – THIRUNELVELI -627002 
                        Br.IV KUZHANTHAI MARTHUVAM 
           POST GRADUATE 
         DISCHARGE SHEET FOR “MANJAL KAMALAI” 
NAME  :   ward   : 
Age/Sex  :       Ip.No  : 
Occupation  / Income       :    Bed . No       : 
Date of Admission  :    
Date of  Discharge  : 
Diagnosis  : 
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Signs and Symptoms   During Admission During Discharge 
Fever   
Nausea   
Vomiting   
Loss of appetite   
Yellow colored urine   
Yellow colored 
conjunctiva 
  
pale colored motion   
General weakness    
Abdominal pain   
Tender and palpable 
liver  
  
Constipation   
Anemia   
Pruritus   
Diarrhoea   
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QUESTIONNAIRE FOR DIAGNOSING JAUNDICE 
 
Name    :- 
Age/Sex   :- 
Father’s Occupation :- 
Mother’s Occupation :- 
Address :- 
FEVER:- 
     Yes    No 
Previous H/O:-  
Malaria   Yes        No 
Typhoid                  Yes                                  No 
Rigor           Yes    No 
         Chills     Yes     No 
NAUSEA:  
  Yes        No 
If Yes, duration:   
VOMITING:  
                                         Yes         No  
If Yes, duration – 
                       Colour – 
LOSS OF APPETITIE: - 
Yes     No 
 If Yes, duration: 
 ABDOMINAL PAIN: -  
    Yes     No 
If Yes, duration     --- 
     Site            --- 
CONSTIPTION:-                Yes                        No 
  
193 
 
If Yes, duration: 
PRUITUS:- 
  Yes     No 
YELLOWISH DISCOLORATION OF URINE:- 
   Yes      No 
HEMATURIA:- 
      Yes       No 
COLOUR OF MOTION:- 
 Normal / Class Colour / Pale Stools / 
LOSS OF WEIGHT:- 
      Yes       No 
LETHARGY:- 
          Yes       No 
DISTURBANCE IN SLEEP RHYTHM:- 
       Yes       No 
DIETARY HABITS:- 
          Yes       No 
TAKING FOOD OUTSIDE:- 
      Yes        No 
HOME FOOD:- 
      Yes        No 
SOURCE OF DRINKING WATER: 
SOCIO-ECONOMIC STATUS:- 
 Good / Moderate / Poor 
FAMILY HISTROY:- 
 No of Family Members:- 
 No of Siblings: 
     Elder    Younger 
 Living in Overcrowded Area: 
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      Yes    No 
  
Family H/O Similar Complaints: 
 Yes    No 
 
DRUG HISTROY:- 
   Yes     No 
 
EXAMINATION:- 
                 HT:   CM   WT:  CM  
           PLUSE:         mins           BP:       mmg 
                 RR:         mins           HR:       mins 
        Cyanosis:   Yes                                      No 
        Clubbing:   Yes     No 
Lymphadenopathy:   Yes         No 
           Oedema: Yes         No 
 
EXAMINATION OF GIT SYSTEM:- 
                            Hepatomegaly / Spleenomegaly / Ascites 
                             CVS SYSTEM:- 
                            RS SYSTEM:- 
DIAGNOSIS:- 
TREATMENT PALN:- 
DATE:- 
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